[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 364
1. Perrotto J, Glick B: Lower extremity malignancies masquerading as ulcers. Ostomy Wound Manage; 2006 Oct;52(10):46-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous malignancies that may masquerade as ulcers include nodulo-ulcerative basal cell carcinoma, squamous cell carcinoma, keratoacanthoma, nodular melanoma, tumor stage mycosis fungoides, lymphomatoid granulomatosis, lymphomatoid papulosis, angiosarcoma, and cutaneous metastases from internal malignancy.
  • [MeSH-major] Neoplasms / diagnosis. Skin Ulcer / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17041254.001).
  • [ISSN] 0889-5899
  • [Journal-full-title] Ostomy/wound management
  • [ISO-abbreviation] Ostomy Wound Manage
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Itoh T, Umekawa K, Rensha K, Minami K, Shoji S, Kitaichi M, Hirata K: [A case of grade I lymphomatoid granulomatosis detected as a solitary lung nodule in a health examination]. Nihon Kokyuki Gakkai Zasshi; 2008 Jan;46(1):50-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of grade I lymphomatoid granulomatosis detected as a solitary lung nodule in a health examination].
  • The pathologic diagnosis of the resected lung was lymphomatoid granulomatosis/angiocentric immunoproliferative lesion (LYG/AIL), grade I.
  • [MeSH-major] Lymphomatoid Granulomatosis / diagnosis

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260311.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Lovinger DM, Homanics GE: Tonic for what ails us? high-affinity GABAA receptors and alcohol. Alcohol; 2007 May;41(3):139-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tonic for what ails us? high-affinity GABAA receptors and alcohol.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHANOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Alcohol Health Res World. 1997;21(2):127-31 [15704348.001]
  • [Cites] J Neurosci. 2004 Nov 24;24(47):10679-86 [15564584.001]
  • [Cites] Pharmacol Ther. 2005 Jul;107(1):80-98 [15963352.001]
  • [Cites] J Neurophysiol. 2005 Dec;94(6):4491-501 [16162835.001]
  • [Cites] J Neurosci. 2005 Dec 14;25(50):11553-63 [16354913.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Mar;316(3):1360-8 [16272217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 30;103(22):8546-51 [16581914.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 30;103(22):8540-5 [16698930.001]
  • [Cites] J Neurophysiol. 2006 Jul;96(1):433-41 [16624993.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15230-5 [17005728.001]
  • [Cites] Nat Neurosci. 2007 Jan;10(1):40-8 [17159992.001]
  • [Cites] Alcohol Clin Exp Res. 1991 Jun;15(3):406-11 [1877727.001]
  • [Cites] Pharmacol Biochem Behav. 1991 Jul;39(3):803-7 [1686108.001]
  • [Cites] Brain Res. 1992 Nov 13;595(2):220-7 [1334772.001]
  • [Cites] Eur J Pharmacol. 1992 Dec 2;224(2-3):173-81 [1281777.001]
  • [Cites] Nature. 1993 Jan 28;361(6410):356-9 [7678923.001]
  • [Cites] FEBS Lett. 1993 Jun 14;324(2):140-2 [8389719.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Mar;268(3):1388-95 [8138953.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Apr;269(1):157-63 [7513357.001]
  • [Cites] Brain Res. 1994 May 30;647(1):97-105 [8069709.001]
  • [Cites] Eur J Pharmacol. 1994 Jul 15;268(2):209-14 [7957642.001]
  • [Cites] J Neurosci. 2004 Apr 14;24(15):3746-51 [15084654.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 14;93(10):5049-54 [8643527.001]
  • [Cites] Physiol Rev. 1997 Jan;77(1):1-20 [9016298.001]
  • [Cites] Mol Pharmacol. 1997 Apr;51(4):588-96 [9106623.001]
  • [Cites] Nature. 1997 Sep 25;389(6649):385-9 [9311780.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Feb;284(2):768-76 [9454826.001]
  • [Cites] Alcohol Clin Exp Res. 1998 Feb;22(1):259-65 [9514316.001]
  • [Cites] Brain Res. 1998 Sep 14;805(1-2):116-22 [9733942.001]
  • [Cites] Psychopharmacology (Berl). 1998 Sep;139(1-2):2-19 [9768538.001]
  • [Cites] Alcohol Clin Exp Res. 1998 Oct;22(7):1516-24 [9802537.001]
  • [Cites] Eur J Neurosci. 1999 Jan;11(1):233-40 [9987027.001]
  • [Cites] Neuropharmacology. 1999 Feb;38(2):253-65 [10218866.001]
  • [Cites] Pharmacol Biochem Behav. 1999 May;63(1):93-9 [10340528.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):10532-8 [11136737.001]
  • [Cites] Nature. 2001 Jan 4;409(6816):88-92 [11343119.001]
  • [Cites] Alcohol Clin Exp Res. 2001 May;25(5 Suppl ISBRA):76S-81S [11391054.001]
  • [Cites] Alcohol Clin Exp Res. 2001 Dec;25(12):1708-18 [11781502.001]
  • [Cites] J Comp Neurol. 2002 Apr 29;446(2):179-97 [11932935.001]
  • [Cites] Alcohol Clin Exp Res. 2002 Apr;26(4):457-62 [11981120.001]
  • [Cites] Nat Neurosci. 2002 Aug;5(8):721-2 [12118257.001]
  • [Cites] Curr Top Med Chem. 2002 Aug;2(8):869-85 [12171577.001]
  • [Cites] Brain Res. 2003 Feb 14;963(1-2):165-77 [12560122.001]
  • [Cites] Brain Res Mol Brain Res. 2003 Feb 20;110(2):289-97 [12591165.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2053-8 [12566570.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14439-44 [14623958.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15218-23 [14625373.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1512-4 [15001778.001]
  • [Cites] Behav Genet. 2004 Jul;34(4):453-63 [15082942.001]
  • [Cites] J Neurosci. 2004 Sep 22;24(38):8379-82 [15385620.001]
  • [Cites] Alcohol. 1984 Jan-Feb;1(1):59-62 [6543611.001]
  • [Cites] Br J Pharmacol. 1985 Jul;85(3):675-81 [2992670.001]
  • [Cites] Science. 1986 Dec 5;234(4781):1243-7 [3022383.001]
  • [Cites] Life Sci. 1987 Aug 3;41(5):611-9 [3600196.001]
  • [Cites] Brain Res. 1987 Jun 23;414(1):22-34 [3620923.001]
  • [Cites] Brain Res. 1988 Jul 12;455(2):377-80 [2900060.001]
  • [Cites] Pharmacol Biochem Behav. 1988 Jun;30(2):501-10 [2845447.001]
  • [Cites] Pharmacol Biochem Behav. 1989 Jan;32(1):163-7 [2543989.001]
  • [Cites] Psychopharmacology (Berl). 1989;99(3):333-6 [2512588.001]
  • [Cites] Brain Res. 1990 Jan 22;507(2):332-6 [2186844.001]
  • [Cites] Nature. 1990 Aug 16;346(6285):648-51 [2166916.001]
  • [Cites] Eur J Pharmacol. 1990 Oct 2;187(1):127-30 [1703076.001]
  • [Cites] Neuron. 1991 Jul;7(1):27-33 [1712603.001]
  • [Cites] Nat Neurosci. 2005 Mar;8(3):339-45 [15696164.001]
  • (PMID = 17521844.001).
  • [ISSN] 0741-8329
  • [Journal-full-title] Alcohol (Fayetteville, N.Y.)
  • [ISO-abbreviation] Alcohol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 AA000407-06
  • [Publication-type] Editorial; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Central Nervous System Depressants; 0 / Receptors, GABA-A; 3K9958V90M / Ethanol
  • [Number-of-references] 63
  • [Other-IDs] NLM/ NIHMS27062; NLM/ PMC2043151
  •  go-up   go-down


Advertisement
4. Mourhatch R, Aswath PB: Nanoscale properties of tribofilms formed with zinc dialkyl dithiophosphate (ZDDP) under extreme pressure condition. J Nanosci Nanotechnol; 2009 Apr;9(4):2682-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Influence of detergents and antioxidants in the base ail on the wear performance was also studied.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438021.001).
  • [ISSN] 1533-4880
  • [Journal-full-title] Journal of nanoscience and nanotechnology
  • [ISO-abbreviation] J Nanosci Nanotechnol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Vanagas G, Padaiga Z, Mickevičienė A: Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania. Medicina (Kaunas); 2010;46(12):835-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nearly 100 new cases of acute hepatitis B are annually registered in Lithuania, but official statistics covers only 8-25% of all disease incidence.
  • RESULTS: Treatment with peginterferon alfa-2a gained 1.179 life years as compared to 0.658 life years gained with treatment with interferon alfa; incremental costs per incremental life-year gained (LYG) were 51,256.92 Lt (14,845.03 €).
  • Treatment with peginterferon alfa-2a gained 0.757 incremental LYG more compared to lamivudine (48-week course).
  • Comparing incremental cost-effectiveness using peginterferon alfa-2a for treatment, incremental costs per incremental LYG were 41,993.67 Lt (12,162.21 €); additionally there was a gain of 0.792 incremental QALYs, while incremental costs for incremental QALY were 40,096.19 Lt (11,612.66 €).

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21532288.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 2T8Q726O95 / Lamivudine; 30IQX730WE / Polyethylene Glycols
  •  go-up   go-down


6. Moore DJ, Miller DM: Laboratory evaluations of insecticide product efficacy for control of Cimex lectularius. J Econ Entomol; 2006 Dec;99(6):2080-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lethal time (LT),, values calculated for the laboratory strain bed bugs indicated that all of the pyrethroid products killed significantly faster than chlorfenapyr (0.5% [AIl; Phantom: BASF; LT50 = 10 d and 9 h).

  • MedlinePlus Health Information. consumer health - Bed Bugs.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17195676.001).
  • [ISSN] 0022-0493
  • [Journal-full-title] Journal of economic entomology
  • [ISO-abbreviation] J. Econ. Entomol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insect Repellents; 0 / Insecticides; 0 / Pyrethrins; NWI20P05EB / chlorfenapyr
  •  go-up   go-down


7. Birger J: What ails health stocks? Fortune; 2005 Nov 14;152(10):219-20, 223-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What ails health stocks?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16300369.001).
  • [ISSN] 0015-8259
  • [Journal-full-title] Fortune
  • [ISO-abbreviation] Fortune
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down


8. Gorelick KJ: What ails the FDA? N Engl J Med; 2005 Jun 16;352(24):2553-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What ails the FDA?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] N Engl J Med. 2005 Mar 17;352(11):1063-6 [15784660.001]
  • (PMID = 15958814.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Lactones; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib
  •  go-up   go-down


9. Siebert U, Sroczynski G, Zietemann V: Pharmacogenomics Bias - Systematic distortion of study results by genetic heterogeneity. GMS Health Technol Assess; 2008;4:Doc03
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Decision analyses of drug treatments in chronic diseases require modeling the progression of disease and treatment response beyond the time horizon of clinical or epidemiological studies.
  • OBJECTIVE: We sought to systematically evaluate the existence, direction and relative magnitude of a pharmacogenomics bias (PGX-Bias) resulting from failure to adjust for genetic heterogeneity in both treatment response (HT) and heterogeneity in progression of disease (HP) in decision-analytic studies based on clinical study data.
  • We constructed two simple Markov models with three basic health states (early-stage disease, late-stage disease, dead), one adjusting and the other not adjusting for genetic heterogeneity.
  • Adjustment was done by creating different disease states for presence (G+) and absence (G-) of a dichotomous genetic factor.
  • Our generic simulation showed that a purely HT-related bias is negative (conservative) and a purely HP-related bias is positive (liberal).
  • In the clinical example with pravastatin therapy, the unadjusted model overestimated the true life-years gained (LYG) by 5.5% (1.07 LYG vs. 0.99 LYG for 56-year-old men).
  • CONCLUSIONS: We have been able to predict the pharmacogenomics bias jointly caused by heterogeneity in progression of disease and heterogeneity in treatment response as a function of characteristics of patients, chronic disease, and treatment.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Decis Making. 2004 Jan-Feb;24(1):102-4 [15005960.001]
  • [Cites] Med Decis Making. 2003 Sep-Oct;23(5):379-96 [14570296.001]
  • [Cites] Med Decis Making. 2003 May-Jun;23(3):232-41 [12809321.001]
  • [Cites] Med Decis Making. 2002 May-Jun;22(3):218-27 [12058779.001]
  • (PMID = 21289909.001).
  • [ISSN] 1861-8863
  • [Journal-full-title] GMS health technology assessment
  • [ISO-abbreviation] GMS Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3011301
  •  go-up   go-down


10. Camidge DR, Oliver JJ, Skinner C, Attwood B, Nussey F, Jodrell D, Webb DJ: The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processes. Br J Clin Pharmacol; 2008 Feb;65(2):224-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: The dominant health economic units upon which new treatment funding decisions are made are the incremental cost per life year gained (LYG) or the cost per quality-adjusted life year (QALY) gained.
  • How certain patients make decisions about their own treatment has previously been explored, but not how they, or doctors, would allocate hypothetical resource within a healthcare system given information on disease-treatment scenarios' prognoses with and without treatment.
  • Individuals use this information in a variety of different ways and a single dominant strategy for quantitative modification of health units is not apparent.
  • Information on prognosis without treatment, or prognosis with standard treatment, is available from the control arm of randomized controlled clinical trials and should be used qualitatively to facilitate decision-making around the second inflexion point on cost per QALY/LYG acceptability curves.
  • The prognoses with and without treatment were varied such that consistent use of one of four potential allocation strategies could be deduced: life years gained (LYGs) - which did not incorporate prognosis without treatment information; percentage increase in life years (PILY); life expectancy with treatment (LEWT) or immediate risk of death (IRD).
  • RESULTS: Random choices were rare; 47% and 64% of doctors and patients, respectively, used prognosis without treatment in their strategies; while 50% and 32%, respectively, used pure LYG-based strategies.
  • Ranking orders were LYG > PILY > IRD > LEWT (doctors) and LEWT > LYG > IRD > PILY (patients).
  • When LYG information alone could not be used, 76% of doctors prioritized shorter prognoses, compared with 45% of patients.

  • MedlinePlus Health Information. consumer health - Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 2003 Sep 13;327(7415):614-5 [12969934.001]
  • [Cites] BMJ. 2004 Jan 17;328(7432):159-61 [14726350.001]
  • [Cites] BMJ. 2004 Jul 24;329(7459):224-7 [15271836.001]
  • [Cites] BMJ. 2004 Oct 23;329(7472):972-5 [15499118.001]
  • [Cites] N Engl J Med. 1994 Feb 24;330(8):545-9 [8302322.001]
  • [Cites] Health Policy. 2006 Apr;76(2):134-43 [15982779.001]
  • [Cites] Arch Intern Med. 1995 Jan 9;155(1):29-40 [7802518.001]
  • [Cites] JAMA. 1998 Jun 3;279(21):1709-14 [9624023.001]
  • [Cites] BMJ. 1998 Jul 18;317(7152):172-5 [9665895.001]
  • [Cites] BMJ. 2005 Jun 11;330(7504):1382-4 [15947403.001]
  • [Cites] Clin Med. 2005 Sep-Oct;5(5):471-5 [16268329.001]
  • [Cites] Hepatology. 1994 Jul;20(1 Pt 2):56S-62S [8005581.001]
  • (PMID = 18251760.001).
  • [ISSN] 1365-2125
  • [Journal-full-title] British journal of clinical pharmacology
  • [ISO-abbreviation] Br J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations
  • [Other-IDs] NLM/ PMC2291216
  •  go-up   go-down


11. Rozenbaum MH, Hak E, van der Werf TS, Postma MJ: Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands. Clin Ther; 2010 Aug;32(8):1517-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Community-acquired pneumonia and invasive pneumococcal disease are common among older people (ie, those aged > or =65 years).
  • Outcome measures included costs, life-years gained (LYGs), quality-adjusted life-years, and incremental cost-effectiveness ratios (ICERs).
  • RESULTS: In the model, the ICER for vaccination remained below euro80,000/LYG, except when the vaccine was assumed to protect only against bacteremic pneumonia, with a relatively low effectiveness (40%) in combination with a high vaccine price (euro65), and indirect effects of serotype replacement would largely offset the direct effect of vaccination.
  • For various assumptions, introduction of widespread PCV-13 vaccination (assuming a 60% efficacy against invasive and noninvasive disease because of vaccine serotypes, and a cost of euro50 per vaccinated person) was associated with the ICERs varying from cost-saving to euro50,676/LYG.
  • The main limitation of this study was uncertainty regarding how great a proportion of pneumonia could be attributed to pneumococcal disease.

  • MedlinePlus Health Information. consumer health - Pneumococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Excerpta Medica Inc. All rights reserved.
  • (PMID = 20728764.001).
  • [ISSN] 1879-114X
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 13-valent pneumococcal vaccine; 0 / Pneumococcal Vaccines
  •  go-up   go-down


12. Schumacher HK, Müller-Nordhorn J, Roll S, Willich SN, Greiner W: Efficacy and effectiveness of recombinant human activated protein C in severe sepsis of adults. GMS Health Technol Assess; 2007;3:Doc05
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESEARCH QUESTIONS: THE FOLLOWING QUESTIONS WERE ANALYSED: is Drotrecogin alfa (activated) (DAA) effective in the treatment of patients with severe sepsis and a mixed risk of death, both in all patients and in different subgroups?
  • RESULTS: Therapy with DAA appears to be cost effective in reducing 28-day-mortality in patients with severe sepsis and a high risk of death.
  • A high risk of death is indicated by the presence of multiorgan failure (≥2) and/or an APACHE-II-Score ≥25.
  • Therapy with DAA is cost-effective in patients with multiorgan failure and/or an APACHE II Score (≥25).
  • DISCUSSION: DAA appears to reduce mortality in patients with severe sepsis and a high risk of death, but not in patients with a low risk of death.
  • In the subgroup of patients with a high risk of death, therapy with DAA ranges at the top level of generally accepted costs per LYG or QALY, in the subgroup of patients with low risk of death, cost effectiveness ratios were higher than those accepted for resource allocation.
  • CONCLUSION: Due to the lack of effectiveness of DAA in patients with severe sepsis and a low risk of death as well as with regard to the high bleeding rates in the usual care setting, indication for DAA therapy.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Crit Care. 2003 Sep;18(3):181-91; discussion 191-4 [14595571.001]
  • [Cites] J Crit Care. 2003 Dec;18(4):217-27 [14691895.001]
  • [Cites] Pharmacoeconomics. 2003;21(18):1331-40 [14750900.001]
  • [Cites] N Engl J Med. 2002 Sep 26;347(13):993-1000 [12324556.001]
  • [Cites] Crit Care Med. 2003 Jan;31(1):1-11 [12544986.001]
  • [Cites] Crit Care Med. 2004 Nov;32(11):2199-206 [15640631.001]
  • [Cites] Anaesthesia. 2005 Feb;60(2):155-62 [15644013.001]
  • [Cites] Am J Ther. 2005 Sep-Oct;12(5):425-30 [16148428.001]
  • [Cites] Int J Technol Assess Health Care. 2006 Winter;22(1):101-8 [16673686.001]
  • (PMID = 21289939.001).
  • [ISSN] 1861-8863
  • [Journal-full-title] GMS health technology assessment
  • [ISO-abbreviation] GMS Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3011332
  •  go-up   go-down


13. Pieper R, Huang ST, Robinson JM, Clark DJ, Alami H, Parmar PP, Perry RD, Fleischmann RD, Peterson SN: Temperature and growth phase influence the outer-membrane proteome and the expression of a type VI secretion system in Yersinia pestis. Microbiology; 2009 Feb;155(Pt 2):498-512
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cell adhesion protein Ail (y1324) and three putative small beta-barrel OM proteins (y1795, y2167 and y4083) were strongly increased at 37 degrees C.
  • The Ail/Lom family protein y1682 (OmpX) was strongly increased at 26 degrees C.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19202098.001).
  • [ISSN] 1350-0872
  • [Journal-full-title] Microbiology (Reading, England)
  • [ISO-abbreviation] Microbiology (Reading, Engl.)
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / N01-AI15447
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Outer Membrane Proteins
  •  go-up   go-down


14. Felek S, Tsang TM, Krukonis ES: Three Yersinia pestis adhesins facilitate Yop delivery to eukaryotic cells and contribute to plague virulence. Infect Immun; 2010 Oct;78(10):4134-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Y. pestis adhesin Ail facilitates Yop translocation and is required for full virulence in mice.
  • In addition to Ail, plasminogen activator (Pla) and pH 6 antigen (Psa) could mediate Yop translocation to host cells.
  • When cells were pregrown at 28°C and pH 7, the order of importance for adhesins in cell binding and cytotoxicity was Ail > Pla > Psa. Y. pestis grown at 37°C and pH 7 had equal contributions from Ail and Pla but an undetectable role for Psa.
  • At 37°C and pH 6, both Ail and Psa contributed to binding and Yop delivery, while Pla contributed minimally.
  • The expression level of ail was also the highest of the three adhesins in infected mouse tissues.
  • Compared to an ail mutant, additional deletion of psaA (encoding Psa) led to a 130,000-fold increase in the 50% lethal dose for mice relative to that of the KIM5 parental strain.
  • Our results indicate that in addition to Ail, Pla and Psa can serve as environmentally specific adhesins to facilitate Yop secretion, a critical virulence function of Y. pestis.

  • MedlinePlus Health Information. consumer health - Plague.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS Pathog. 2008 Jan;4(1):e3 [18193942.001]
  • [Cites] PLoS Med. 2008 Jan 15;5(1):e3 [18198939.001]
  • [Cites] Infect Dis Clin North Am. 2008 Mar;22(1):145-87, vii [18295687.001]
  • [Cites] Microbiology. 2008 Jun;154(Pt 6):1802-12 [18524935.001]
  • [Cites] Infect Immun. 2008 Sep;76(9):4100-9 [18625735.001]
  • [Cites] PLoS Pathog. 2008;4(8):e1000140 [18769718.001]
  • [Cites] J Biol Chem. 2008 Nov 14;283(46):31511-21 [18650418.001]
  • [Cites] J Med Microbiol. 2009 Jan;58(Pt 1):26-36 [19074650.001]
  • [Cites] Infect Immun. 2009 Feb;77(2):825-36 [19064637.001]
  • [Cites] Microbiology. 2009 Feb;155(Pt 2):498-512 [19202098.001]
  • [Cites] J Basic Microbiol. 2009 Feb;49(1):92-9 [18759226.001]
  • [Cites] Infect Immun. 2010 Aug;78(8):3358-68 [20498264.001]
  • [Cites] Methods. 2000 Jun;21(2):179-83 [10816379.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):5978-83 [10811905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6640-5 [10829079.001]
  • [Cites] Infect Immun. 2000 Aug;68(8):4523-30 [10899851.001]
  • [Cites] Eur J Cell Biol. 2000 Oct;79(10):659-71 [11089914.001]
  • [Cites] Mol Microbiol. 2001 Jun;40(5):1097-111 [11401715.001]
  • [Cites] FEBS Lett. 2001 Aug 24;504(1-2):69-72 [11522299.001]
  • [Cites] Nature. 2001 Oct 4;413(6855):523-7 [11586360.001]
  • [Cites] Infect Immun. 2002 Mar;70(3):1453-60 [11854232.001]
  • [Cites] Science. 2002 Apr 26;296(5568):733-5 [11976454.001]
  • [Cites] J Bacteriol. 2002 Aug;184(16):4601-11 [12142430.001]
  • [Cites] Microb Pathog. 2002 Dec;33(6):265-77 [12495673.001]
  • [Cites] Mol Microbiol. 2003 Feb;47(3):807-23 [12535078.001]
  • [Cites] J Lipid Res. 2003 Feb;44(2):320-30 [12576514.001]
  • [Cites] Infect Immun. 1986 Feb;51(2):445-54 [3002984.001]
  • [Cites] Nature. 1988 Aug 11;334(6182):522-4 [3043229.001]
  • [Cites] Microb Pathog. 1989 Mar;6(3):203-17 [2739560.001]
  • [Cites] Mol Microbiol. 1990 Apr;4(4):657-67 [2191183.001]
  • [Cites] Infect Immun. 1990 Aug;58(8):2569-77 [2164509.001]
  • [Cites] Gene. 1991 Jan 2;97(1):39-47 [1847347.001]
  • [Cites] Infect Immun. 1991 Dec;59(12):4562-9 [1937815.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3561-5 [1565652.001]
  • [Cites] J Gen Microbiol. 1992 Aug;138 Pt 8:1679-87 [1527508.001]
  • [Cites] Science. 1992 Nov 6;258(5084):1004-7 [1439793.001]
  • [Cites] Mol Microbiol. 1992 Sep;6(18):2693-704 [1447977.001]
  • [Cites] Cell. 1993 Apr 23;73(2):381-93 [8386592.001]
  • [Cites] Infect Immun. 1993 May;61(5):1846-52 [7682996.001]
  • [Cites] Mol Microbiol. 1993 Apr;8(2):311-24 [8100346.001]
  • [Cites] Infect Immun. 1995 Aug;63(8):3117-24 [7622239.001]
  • [Cites] J Bacteriol. 1995 Oct;177(20):5997-6000 [7592356.001]
  • [Cites] Infect Immun. 1996 Jan;64(1):375-9 [8557370.001]
  • [Cites] EMBO J. 1995 Dec 1;14(23):5957-64 [8846788.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2483-9 [8698470.001]
  • [Cites] FEMS Immunol Med Microbiol. 1996 May;14(1):53-7 [8804976.001]
  • [Cites] Clin Microbiol Rev. 1997 Jan;10(1):35-66 [8993858.001]
  • [Cites] Infect Immun. 1997 May;65(5):1659-68 [9125544.001]
  • [Cites] Mol Microbiol. 1997 May;24(3):499-510 [9179844.001]
  • [Cites] Microb Pathog. 1997 Oct;23(4):211-23 [9344782.001]
  • [Cites] Infect Immun. 1997 Nov;65(11):4813-21 [9353070.001]
  • [Cites] Infect Immun. 1998 Sep;66(9):4545-8 [9712817.001]
  • [Cites] Mol Microbiol. 1998 Aug;29(3):915-29 [9723929.001]
  • [Cites] Infect Immun. 1998 Dec;66(12):5755-62 [9826351.001]
  • [Cites] Microbiol Mol Biol Rev. 1998 Dec;62(4):1315-52 [9841674.001]
  • [Cites] Science. 1999 Sep 17;285(5435):1920-3 [10489373.001]
  • [Cites] J Bacteriol. 1963 Jul;86:101-11 [14051801.001]
  • [Cites] Infect Immun. 2004 Dec;72(12):7212-9 [15557646.001]
  • [Cites] Curr Opin Microbiol. 2005 Feb;8(1):21-7 [15694853.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17786-91 [16306265.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5526-30 [16567636.001]
  • [Cites] FEMS Microbiol Lett. 2006 Sep;262(2):158-62 [16923070.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13514-9 [16938880.001]
  • [Cites] Science. 2007 Jan 26;315(5811):509-13 [17255510.001]
  • [Cites] Infect Immun. 2007 Mar;75(3):1272-9 [17178780.001]
  • [Cites] Microbiology. 2007 Sep;153(Pt 9):2941-51 [17768237.001]
  • [Cites] Adv Exp Med Biol. 2007;603:97-105 [17966407.001]
  • [Cites] Infect Immun. 2008 Feb;76(2):612-22 [18025094.001]
  • [Cites] Infect Immun. 1988 Oct;56(10):2749-52 [2843471.001]
  • [Cites] Microb Pathog. 1987 Oct;3(4):239-48 [3504547.001]
  • [Cites] Infect Immun. 1989 Apr;57(4):1200-10 [2925246.001]
  • (PMID = 20679446.001).
  • [ISSN] 1098-5522
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC2950350
  •  go-up   go-down


15. Bennett K, Kabir Z, Barry M, Tilson L, Fidan D, Shelley E, Capewell S: Cost-effectiveness of treatments reducing coronary heart disease mortality in Ireland, 2000 to 2010. Value Health; 2009 Jan-Feb;12(1):10-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of treatments reducing coronary heart disease mortality in Ireland, 2000 to 2010.
  • OBJECTIVE: Coronary heart disease (CHD) is associated with a large burden of disease in Ireland and is responsible for more than 6000 deaths annually.
  • This model calculates the number of life-years gained (LYGs) by specific cardiology interventions to generate incremental cost-effectiveness ratios (ICERs) per LYG for each intervention.
  • Aspirin, beta-blockers, ACE inhibitors, spironolactone, and warfarin for specific conditions were the most cost-effective interventions (< euro 3000/LYG), followed by the statins for secondary prevention (< euro 6500/LYG).
  • Revascularization for chronic angina and primary angioplasty for myocardial infarction, although still cost-effective, had the highest ICER (between euro 12,000 and euro 20,000/LYG).
  • [MeSH-major] Coronary Disease / economics. Coronary Disease / prevention & control. Life Expectancy / trends

  • Genetic Alliance. consumer health - Heart Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19040564.001).
  • [ISSN] 1524-4733
  • [Journal-full-title] Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • [ISO-abbreviation] Value Health
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0500920
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Yu X, Teng H, Marques A, Ashgari F, Ibrahim SM: High resolution mapping of Cia3: a common arthritis quantitative trait loci in different species. J Immunol; 2009 Mar 1;182(5):3016-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Major CIA clinical traits were evaluated in both (DBA/1xFVB/N) F(2) and advanced intercross line (AIL) mice; QTLs were confirmed and refined in AIL.
  • We identified six suggestive QTLs controlling CIA clinical traits in the F(2) progeny; one of these was confirmed and refined in AIL.
  • [MeSH-minor] Age of Onset. Animals. Arthritis, Rheumatoid / diagnosis. Arthritis, Rheumatoid / genetics. Arthritis, Rheumatoid / immunology. Comparative Genomic Hybridization. Crosses, Genetic. Gene Expression Profiling. Genetic Linkage / immunology. Genetic Markers / immunology. Genetic Predisposition to Disease. Humans. Mice. Mice, Inbred DBA. Polymorphism, Genetic / immunology. Rats. Severity of Illness Index


17. Makoschey B, Beer M: A live bovine herpesvirus-1 marker vaccine is not shed after intramuscular vaccination. Berl Munch Tierarztl Wochenschr; 2007 Nov-Dec;120(11-12):480-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIl animals were successfully vaccinated as judged by the development of BHV-1 neutralising antibodies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18085158.001).
  • [ISSN] 0005-9366
  • [Journal-full-title] Berliner und Münchener tierärztliche Wochenschrift
  • [ISO-abbreviation] Berl. Munch. Tierarztl. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / DNA, Viral; 0 / Vaccines, Attenuated; 0 / Vaccines, Marker; 0 / Viral Vaccines
  •  go-up   go-down


18. Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S: Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine. Schizophr Res; 2008 Oct;105(1-3):224-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Amisulpride's effects on amphetamine and phencyclidine induced locomotor activity (AIL/PIL), conditioned avoidance response, catalepsy (CAT), subcortical Fos expression, and plasma prolactin was correlated to its time-course striatal D2/3 and prefrontal 5-HT2 receptor occupancy (D(2/3)/5-HT2RO); in comparison to haloperidol, clozapine, and risperidone.
  • CONCLUSIONS: Amisulpride's "delayed" functional profile on acute administration and the need for high doses is most likely due to its poor blood-brain-barrier penetration; however, it is distinct from other atypicals in showing low motor side-effects, activity against phencyclidine, and a mesolimbic preference, despite no action on serotonin receptors.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RISPERIDONE .
  • Hazardous Substances Data Bank. AMPHETAMINE .
  • Hazardous Substances Data Bank. HALOPERIDOL .
  • Hazardous Substances Data Bank. CLOZAPINE .
  • Hazardous Substances Data Bank. PHENCYCLIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18710798.001).
  • [ISSN] 0920-9964
  • [Journal-full-title] Schizophrenia research
  • [ISO-abbreviation] Schizophr. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Receptors, Dopamine; 0 / Receptors, Dopamine D2; 0 / Receptors, Dopamine D3; 0 / Receptors, Serotonin; 7MNE9M8287 / Sulpiride; 9002-62-4 / Prolactin; AA0G3TW31W / sultopride; CK833KGX7E / Amphetamine; J1DOI7UV76 / Phencyclidine; J60AR2IKIC / Clozapine; J6292F8L3D / Haloperidol; L6UH7ZF8HC / Risperidone
  •  go-up   go-down


19. Kaur M, Singh K, Rup PJ, Kamboj SS, Singh J: Anti-insect potential of lectins from Arisaema species towards Bactrocera cucurbitae. J Environ Biol; 2009 Nov;30(6):1019-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total development period was found to be prolonged by 3.5 and 2.3 days in case of larvae fed on artificial diet containing A. intermedium (AIL) and A. wallichianum (AWL), respectively.
  • LC50 values calculated on the basis of adult emergence came out to be 32.8 and 29 microg ml(-1) for AIL and AWL, respectively.
  • The activity of acid phosphatase decreased significantly in larvae reared on diet containing LC50 of AIL, while in case of AWL significant decrease was observed only at 72 hr of treatment.
  • These results showed that AIL and AWL have promising anti-insect potential.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20329399.001).
  • [ISSN] 0254-8704
  • [Journal-full-title] Journal of environmental biology
  • [ISO-abbreviation] J Environ Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Insecticides; 0 / Lectins
  •  go-up   go-down


20. Martínez PO, Fredriksson-Ahomaa M, Sokolova Y, Roasto M, Berzins A, Korkeala H: Prevalence of enteropathogenic Yersinia in Estonian, Latvian, and Russian (Leningrad region) pigs. Foodborne Pathog Dis; 2009 Jul-Aug;6(6):719-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathogenic Y. enterocolitica and Y. pseudotuberculosis were identified by PCR targeting the chromosomal genes ail and inv, respectively.
  • The prevalence of ail-positive Y. enterocolitica was 89% in Estonia, 64% in Latvia, and 34% in Russia, with 81% of ail-positive samples being virF-positive.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19580449.001).
  • [ISSN] 1556-7125
  • [Journal-full-title] Foodborne pathogens and disease
  • [ISO-abbreviation] Foodborne Pathog. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Zárate G, Chaia AP: Dairy bacteria remove in vitro dietary lectins with toxic effects on colonic cells. J Appl Microbiol; 2009 Mar;106(3):1050-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To assess in vitro the ability of some dairy bacteria to bind concanavalin A (Con A), peanut agglutinin (PNA) and jacalin (AIL), preventing their toxicity on mouse intestinal epithelial cells (IEC).
  • METHODS AND RESULTS: Con A and AIL reduced significantly IEC viability in vitro, as determined by Trypan Blue dye exclusion or by propidium iodide/fluorescein diacetate/Hoescht staining.
  • Con A and AIL were removed by Propionibacterium acidipropionici and Propionibacterium freudenreichii by binding with specific sugar moieties on the bacterial surface.
  • Adhesion of P. acidipropionici to IEC was reduced but not abolished after binding Con A or AIL.
  • CONCLUSIONS: Removal of Con A or AIL by dairy propionibacteria was effective to avoid the toxic effect against colonic cells in vitro.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19191953.001).
  • [ISSN] 1365-2672
  • [Journal-full-title] Journal of applied microbiology
  • [ISO-abbreviation] J. Appl. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lectins; 0 / Plant Lectins; 0 / jacalin; 11028-71-0 / Concanavalin A
  •  go-up   go-down


22. Beck EJ, Mandalia S, Youle M, Brettle R, Fisher M, Gompels M, Kinghorn G, McCarron B, Pozniak A, Tang A, Walsh J, Williams I, Gazzard B: Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002). Int J STD AIDS; 2008 May;19(5):297-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to estimate the outcome and cost-effectiveness per life-year-gained (LYG) of first-, second- and third-line non-nucleoside reverse transcriptase inhibitors (NNRTI) versus protease inhibitor (PI) containing highly active antiretroviral therapy regimens.
  • Comparing first-line 2NRTIs + NNRTI with 2NRTIs + PI(boosted) cost per LYG was US$ 12,375; US$ 12,139 per LYG when compared with 2NRTIs + PI and US$ 2948 per LYG when compared with 2NRTIs + 2PIs.
  • For second-line cost per LYG comparing 2NRTIs + NNRTI with 2NRTIs + PI(boosted) was US$ 19,501; US$ 18,364 per LYG when compared with 2NRTIs + PI and cost-saving when compared with 2NRTIs + 2PIs.
  • For third-line cost per LYG comparing 2NRTIs + NNRTI with 2NRTIs + PI(boosted) was US$ 2708; US$ 11,559 per LYG when compared with 2NRTIs + PI and cost-saving when compared with 2NRTIs + 2PIs.


23. Best medicines for less: we compare drugs for what ails America. Consum Rep; 2008 Jan;73(1):27-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Best medicines for less: we compare drugs for what ails America.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18488284.001).
  • [ISSN] 0010-7174
  • [Journal-full-title] Consumer reports
  • [ISO-abbreviation] Consum Rep
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drugs, Generic
  •  go-up   go-down


24. Wang D, Cummins C, Bayliss S, Sandercock J, Burls A: Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess; 2008 Dec;12(36):iii, ix-x, 1-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prophylaxis with palivizumab for preterm infants without chronic lung disease (CLD) or children with CLD resulted in a 55% reduction in RSV hospital admission: 4.8% (48/1002) in the palivizumab group and 10.6% (53/500) in the no prophylaxis group (p = 0.0004).
  • Prophylaxis with palivizumab was associated with a 45% reduction in hospitalisation rate RSV among children with coronary heart disease (CHD).
  • The incremental cost-effectiveness ratios (ICERs) of the primary studies varied 17-fold for life-years gained (LYG), from 25,800 pounds/LYG to 404,900 pounds/LYG, and several hundred-fold for quality-adjusted life-years (QALYs), from 3200 pounds/QALY to 1,489,700 pounds/QALY for preterm infants without CLD or children with CLD.
  • For children with CHD, the ICER varied from 5300 pounds/LYG to 7900 pounds/LYG and from 7500 pounds/QALY to 68,700 pounds/QALY.

  • MedlinePlus Health Information. consumer health - Respiratory Syncytial Virus Infections.
  • Hazardous Substances Data Bank. Palivizumab .
  • PubMed Health. PubMed Health .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19049692.001).
  • [ISSN] 2046-4924
  • [Journal-full-title] Health technology assessment (Winchester, England)
  • [ISO-abbreviation] Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antiviral Agents; DQ448MW7KS / Palivizumab
  • [Number-of-references] 79
  •  go-up   go-down


25. McCullagh L, Tilson L, Walsh C, Barry M: A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting. Pharmacoeconomics; 2009;27(10):829-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Separate models for the disease states THR and TKR were run to accommodate the different venous thromboembolism risks associated with each procedure.
  • Outcome measures were QALYs and life-years gained (LYG).
  • The incremental cost-effectiveness ratios for dabigatran etexilate relative to enoxaparin were euro 23,934 per LYG and euro 17,835 per QALY.

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 1997 Jul-Aug;82(4):423-8 [9299855.001]
  • [Cites] Arch Orthop Trauma Surg. 2004 Oct;124(8):507-17 [15365714.001]
  • [Cites] Br J Haematol. 2003 Apr;121(1):12-20 [12670327.001]
  • [Cites] Med Decis Making. 1997 Jul-Sep;17(3):276-84 [9219187.001]
  • [Cites] Pharmacoeconomics. 2003;21(7):477-96 [12696988.001]
  • [Cites] Arch Intern Med. 1998 Jul 27;158(14):1525-31 [9679793.001]
  • [Cites] CMAJ. 2003 Jan 21;168(2):183-94 [12538548.001]
  • [Cites] J Am Med Inform Assoc. 1997 Jan-Feb;4(1):49-56 [8988474.001]
  • [Cites] Pharmacotherapy. 2002 Aug;22(8):990-1000 [12173802.001]
  • [Cites] Chest. 2008 Jun;133(6 Suppl):381S-453S [18574271.001]
  • [Cites] J Thromb Haemost. 2007 Nov;5(11):2178-85 [17764540.001]
  • [Cites] Chest. 1995 Oct;108(4):978-81 [7555172.001]
  • [Cites] Br J Haematol. 2006 Feb;132(3):277-85 [16409292.001]
  • [Cites] Obstet Gynecol. 2004 Sep;104(3):433-42 [15339751.001]
  • [Cites] BMJ. 2003 Mar 1;326(7387):472 [12609941.001]
  • [Cites] Arch Intern Med. 1999 Mar 8;159(5):445-53 [10074952.001]
  • [Cites] Arch Intern Med. 1995 Apr 10;155(7):757-64 [7695464.001]
  • [Cites] Value Health. 2008 Sep-Oct;11(5):886-97 [18489513.001]
  • [Cites] Clin Ther. 2002 Nov;24(11):1960-86; discussion 1938 [12501885.001]
  • [Cites] Clin Ther. 2009 Jan;31(1):194-212 [19243718.001]
  • [Cites] Arch Intern Med. 1988 Jun;148(6):1425-6 [3377625.001]
  • [Cites] Chest. 2004 Sep;126(3 Suppl):338S-400S [15383478.001]
  • [Cites] Chest. 2004 Sep;126(3 Suppl):401S-428S [15383479.001]
  • [Cites] Ann Intern Med. 1981 Apr;94(4 pt 1):439-44 [7212500.001]
  • [Cites] JAMA. 1998 Feb 11;279(6):458-62 [9466640.001]
  • [Cites] Pharmacoeconomics. 2008;26(9):753-67 [18767896.001]
  • [Cites] Value Health. 2005 Jul-Aug;8(4):433-46 [16091019.001]
  • [Cites] Semin Thromb Hemost. 2001;27(1):3-8 [11288945.001]
  • [Cites] Expert Rev Pharmacoecon Outcomes Res. 2007 Dec;7(6):605-11 [20528322.001]
  • [Cites] Lancet. 2008 Feb 2;371(9610):387-94 [18242412.001]
  • [Cites] Value Health. 2003 Jan-Feb;6(1):9-17 [12535234.001]
  • [Cites] Pharmacoeconomics. 2008;26(9):781-98 [18767898.001]
  • [Cites] JAMA. 1987 Jan 9;257(2):203-8 [3098991.001]
  • [Cites] BMJ. 1996 Aug 3;313(7052):275-83 [8704542.001]
  • [Cites] J Thromb Haemost. 2003 Oct;1(10):2167-74 [14521600.001]
  • [Cites] Lancet. 1985 Sep 7;2(8454):515-8 [2863541.001]
  • [Cites] Med Decis Making. 2003 Jul-Aug;23 (4):341-50 [12926584.001]
  • [Cites] Value Health. 2005 Jan-Feb;8(1):1-2 [15841888.001]
  • [Cites] Lancet. 2007 Sep 15;370(9591):949-56 [17869635.001]
  • [Cites] Am Fam Physician. 2004 Jun 15;69(12):2841-8 [15222649.001]
  • [Cites] Lancet. 2008 Jul 5;372(9632):31-9 [18582928.001]
  • [Cites] N Engl J Med. 2008 Jun 26;358(26):2776-86 [18579812.001]
  • (PMID = 19803538.001).
  • [ISSN] 1170-7690
  • [Journal-full-title] PharmacoEconomics
  • [ISO-abbreviation] Pharmacoeconomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Benzimidazoles; 0 / Enoxaparin; 0 / Fibrinolytic Agents; 0 / Morpholines; 0 / Pyridines; 0 / Thiophenes; 9NDF7JZ4M3 / Rivaroxaban; I0VM4M70GC / Dabigatran
  •  go-up   go-down


26. Zhang Z, Mahoney EM, Kolm P, Spertus J, Caro J, Willke R, Weintraub WS: Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS. Am J Cardiovasc Drugs; 2010;10(1):55-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure and Survival Study) showed that the use of aldosterone blockade with eplerenone decreased mortality in patients with heart failure after acute myocardial infarction, and a subsequent analysis showed eplerenone to be highly cost effective in this population.
  • The incremental cost effectiveness of eplerenone in cost per life-year gained (LYG) and cost per quality-adjusted life-year (QALY) gained beyond the trial period was estimated using data from the Framingham Heart Study, the Saskatchewan Health database, and the Worcester Heart Attack Registry.
  • The number of LYGs with eplerenone compared with placebo was 0.1665 based on the Framingham data, 0.0979 using the Saskatchewan data, and 0.2172 using the Worcester data.
  • The incremental cost-effectiveness ratio (ICER) was $US10,288/LYG with the Framingham data, $US17,506/LYG with the Saskatchewan data, and $US7888/LYG with the Worcester data (99% <$US50,000/LYG for all three sources).

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SPIRONOLACTONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20104935.001).
  • [ISSN] 1175-3277
  • [Journal-full-title] American journal of cardiovascular drugs : drugs, devices, and other interventions
  • [ISO-abbreviation] Am J Cardiovasc Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Mineralocorticoid Receptor Antagonists; 27O7W4T232 / Spironolactone; 6995V82D0B / eplerenone
  •  go-up   go-down


27. Tsutani K, Igarashi A, Fujikawa K, Evers T, Kubin M, Lamotte M, Annemans L: A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan. Intern Med; 2007;46(4):157-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.
  • OBJECTIVE: Low-dose aspirin is standard care in patients with a history of cardiovascular disease (CVD).
  • Direct costs from the insurers' perspective were used, while health outcome was expressed in Life-Years Gained (LYG).
  • RESULTS: For patients with a 1-year risk of coronary heart disease (CHD) of 1.5% (10-year risk of +/-15%), the model demonstrated 'dominance' of the 'aspirin' arm versus 'no aspirin' arm; the 10-year costs were Japanese Yen (JPY) 634,000 (Euro 4,857) and JPY 518,000 (Euro 3,968) in the 'no aspirin' arm and 'aspirin' arm, respectively, while LYG was 8.33 and 8.36, respectively.

  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Intern Med. 2007;46(15):1281 [17675791.001]
  • [CommentIn] Intern Med. 2007;46(8):431-3 [17443030.001]
  • (PMID = 17301509.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] R16CO5Y76E / Aspirin
  •  go-up   go-down


28. Divgi C: Editorial: what ails solid tumor radioimmunotherapy? Cancer Biother Radiopharm; 2006 Apr;21(2):81-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Editorial: what ails solid tumor radioimmunotherapy?

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. Trastuzumab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16706627.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, Neoplasm; 0 / ibritumomab tiuxetan; 0 / iodine-131 anti-B1 antibody; 4F4X42SYQ6 / Rituximab; P188ANX8CK / Trastuzumab
  •  go-up   go-down


29. Felek S, Krukonis ES: The Yersinia pestis Ail protein mediates binding and Yop delivery to host cells required for plague virulence. Infect Immun; 2009 Feb;77(2):825-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Yersinia pestis Ail protein mediates binding and Yop delivery to host cells required for plague virulence.
  • The mutants that emerged contained insertions within the ail (attachment and invasion locus) gene of Y. pestis.
  • A reconstructed mutant with a single deletion in the ail locus (y1324) was severely defective for delivery of Yops to HEp-2 human epithelial cells and significantly defective for delivery of Yops to THP-1 human monocytes.
  • Although the ail mutant showed only a modest decrease in cell binding capacity in vitro, the KIM5 Deltaail mutant exhibited a >3,000-fold-increased 50% lethal dose in mice.
  • Thus, the Ail protein is critical for both Y. pestis type III secretion in vitro and infection in mice.

  • MedlinePlus Health Information. consumer health - Plague.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1993 Feb 25;361(6414):730-2 [8441468.001]
  • [Cites] J Gen Microbiol. 1992 Aug;138 Pt 8:1679-87 [1527508.001]
  • [Cites] Infect Immun. 1993 May;61(5):1846-52 [7682996.001]
  • [Cites] Infect Immun. 1995 Jul;63(7):2541-8 [7790067.001]
  • [Cites] Infect Immun. 1996 Jan;64(1):375-9 [8557370.001]
  • [Cites] EMBO J. 1995 Dec 1;14(23):5957-64 [8846788.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2483-9 [8698470.001]
  • [Cites] Clin Microbiol Rev. 1997 Jan;10(1):35-66 [8993858.001]
  • [Cites] Infect Immun. 1997 May;65(5):1659-68 [9125544.001]
  • [Cites] Mol Microbiol. 1998 Mar;27(5):953-65 [9535085.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13658-63 [9811856.001]
  • [Cites] Infect Immun. 1998 Dec;66(12):5755-62 [9826351.001]
  • [Cites] Microbiol Mol Biol Rev. 1998 Dec;62(4):1315-52 [9841674.001]
  • [Cites] J Exp Med. 1998 Dec 7;188(11):2127-37 [9841926.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1645-50 [9990078.001]
  • [Cites] Infect Immun. 1999 Sep;67(9):4851-61 [10456941.001]
  • [Cites] Science. 1999 Sep 17;285(5435):1920-3 [10489373.001]
  • [Cites] Mol Microbiol. 2005 May;56(3):590-603 [15819617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17786-91 [16306265.001]
  • [Cites] Infect Immun. 2006 Mar;74(3):1516-27 [16495522.001]
  • [Cites] Science. 2006 May 26;312(5777):1211-4 [16728640.001]
  • [Cites] PLoS Pathog. 2005 Oct;1(2):e16 [16228016.001]
  • [Cites] FEMS Microbiol Lett. 2006 Sep;262(2):158-62 [16923070.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13514-9 [16938880.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1066-73 [16980981.001]
  • [Cites] Infect Immun. 2006 Oct;74(10):5636-44 [16988239.001]
  • [Cites] Microbiology. 2007 Sep;153(Pt 9):2941-51 [17768237.001]
  • [Cites] Infect Immun. 2008 Feb;76(2):612-22 [18025094.001]
  • [Cites] PLoS Pathog. 2008 Jan;4(1):e3 [18193942.001]
  • [Cites] PLoS One. 2008;3(2):e1688 [18301765.001]
  • [Cites] Microbiology. 2008 Jun;154(Pt 6):1802-12 [18524935.001]
  • [Cites] Structure. 1999 Oct 15;7(10):1301-9 [10545325.001]
  • [Cites] J Biotechnol. 2000 Apr 14;79(1):63-72 [10817342.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):5978-83 [10811905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6640-5 [10829079.001]
  • [Cites] Mol Microbiol. 2000 May;36(3):737-48 [10844661.001]
  • [Cites] Infect Immun. 2000 Aug;68(8):4523-30 [10899851.001]
  • [Cites] Mol Microbiol. 2000 Aug;37(3):515-27 [10931345.001]
  • [Cites] Eur J Cell Biol. 2000 Oct;79(10):659-71 [11089914.001]
  • [Cites] Science. 2000 Nov 24;290(5496):1594-7 [11090361.001]
  • [Cites] FEBS Lett. 2001 Aug 24;504(1-2):69-72 [11522299.001]
  • [Cites] FEBS Lett. 2001 Aug 31;504(3):173-8 [11532450.001]
  • [Cites] Mol Microbiol. 2001 Sep;41(5):1053-62 [11555286.001]
  • [Cites] EMBO J. 2001 Oct 1;20(19):5373-82 [11574469.001]
  • [Cites] Nature. 2001 Oct 4;413(6855):523-7 [11586360.001]
  • [Cites] Mol Microbiol. 2001 Nov;42(3):689-703 [11722735.001]
  • [Cites] J Bacteriol. 2002 Aug;184(16):4601-11 [12142430.001]
  • [Cites] Microb Pathog. 2002 Dec;33(6):265-77 [12495673.001]
  • [Cites] Mol Microbiol. 2003 Feb;47(3):807-23 [12535078.001]
  • [Cites] Adv Exp Med Biol. 2003;529:79-84 [12756732.001]
  • [Cites] Infect Immun. 2003 Aug;71(8):4595-607 [12874339.001]
  • [Cites] Mol Microbiol. 2004 Jun;52(5):1363-73 [15165239.001]
  • [Cites] Infect Immun. 2004 Aug;72(8):4589-602 [15271919.001]
  • [Cites] Infect Immun. 1988 May;56(5):1242-8 [2833444.001]
  • [Cites] Nature. 1988 Aug 11;334(6182):522-4 [3043229.001]
  • [Cites] Infect Immun. 1989 Apr;57(4):1200-10 [2925246.001]
  • [Cites] J Exp Med. 1989 Nov 1;170(5):1727-36 [2572672.001]
  • [Cites] Mol Microbiol. 1990 Apr;4(4):657-67 [2191183.001]
  • [Cites] Infect Immun. 1990 Aug;58(8):2569-77 [2164509.001]
  • [Cites] Gene. 1991 Jan 2;97(1):39-47 [1847347.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1187-91 [1705028.001]
  • [Cites] J Bacteriol. 1991 Sep;173(17):5298-307 [1679429.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3561-5 [1565652.001]
  • [Cites] Cell. 1993 Apr 23;73(2):381-93 [8386592.001]
  • (PMID = 19064637.001).
  • [ISSN] 1098-5522
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Ail protein, Yersinia pestis; 0 / Bacterial Outer Membrane Proteins; 0 / Bacterial Proteins; 0 / DNA Transposable Elements; 0 / Membrane Transport Proteins; 0 / Virulence Factors; 0 / YscC protein, Yersinia pestis
  • [Other-IDs] NLM/ PMC2632051
  •  go-up   go-down


30. Gu L, Wang H, Zhu FC, Shi ZY, Zeng XY, Tan ZY, Xiao YC, Qiu HY, Wang X, Jin D, Cui ZG, Wang B, Kan B, Wang XS, Jing HQ, Xu JG: [Study on the distribution of Yersinia enterocolitica in Nantong, Jinagsu Province]. Zhonghua Liu Xing Bing Xue Za Zhi; 2005 Oct;26(10):786-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The combined isolation rate of Yersinia enterocolitica from livestock and poultry was 31.06% and the gene distribution characters were: 39.57% of them were ail-, ystA- , ystB-, yadA- , virF-; 60.43% were ail- , ystA- , ystB + , yadA- , virF- respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16536305.001).
  • [ISSN] 0254-6450
  • [Journal-full-title] Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
  • [ISO-abbreviation] Zhonghua Liu Xing Bing Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Virulence Factors
  •  go-up   go-down


31. Conde C: Curing what ails us: new report says Texans' health declining. Tex Med; 2009 Mar;105(3):18-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curing what ails us: new report says Texans' health declining.

  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Smoking.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19263301.001).
  • [ISSN] 1938-3223
  • [Journal-full-title] Texas medicine
  • [ISO-abbreviation] Tex Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Simons J: A new CEO'S RX for what ails Merck. Fortune; 2005 May 30;151(11):28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new CEO'S RX for what ails Merck.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15926519.001).
  • [ISSN] 0015-8259
  • [Journal-full-title] Fortune
  • [ISO-abbreviation] Fortune
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down


33. Pfistershammer K, Petzelbauer P, Stingl G, Mastan P, Chott A, Jäger U, Skrabs C, Geusau A: Methotrexate-induced primary cutaneous diffuse large B-cell lymphoma with an 'angiocentric' histological morphology. Clin Exp Dermatol; 2010 Jan;35(1):59-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methotrexate-induced primary cutaneous diffuse large B-cell lymphoma with an 'angiocentric' histological morphology.
  • A patient with a 25-year history of rheumatoid arthritis and a 3-year history of methotrexate treatment developed a generalized papular rash.
  • The rapid course of lesion development and regression was reminiscent of pityriasis lichenoides.
  • The T cells had a striking angiocentric distribution, with some of the vessels exhibiting fibrinoid necrosis of the vessel wall reminiscent of lymphomatoid granulomatosis.
  • [MeSH-minor] Aged. B-Lymphocytes / pathology. Diagnosis, Differential. Female. Humans. Pityriasis Lichenoides / pathology. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19486063.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


34. Boersma C, Carides GW, Atthobari J, Voors AA, Postma MJ: An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. Clin Ther; 2007 May;29(5):963-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The Losartan Intervention For Endpoint reduction (LIFE) study was a randomized, doubleblind trial that compared the effects of losartan-based treatment with those of atenolol-based treatment on cardiovascular disease (CVD)-related morbidity and mortality in 9193 patients with hypertension and left-ventricular hypertrophy (LVH).
  • As a consequence, losartan treatment was associated with 0.059 life-year gained (LYG) per patient treated with losartan.
  • The net cost per LYG was 864 Euros ($1083), which is below the Dutch pharmacoeconomic threshold of 20,000 Euros/LYG (~$25,000/LYG) for accepting interventions.

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Losartan .
  • Hazardous Substances Data Bank. ATENOLOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697915.001).
  • [ISSN] 0149-2918
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 50VV3VW0TI / Atenolol; JMS50MPO89 / Losartan
  •  go-up   go-down


35. Hu WS, Li PC, Cheng CY: Correlation between ceftriaxone resistance of Salmonella enterica serovar Typhimurium and expression of outer membrane proteins OmpW and Ail/OmpX-like protein, which are regulated by BaeR of a two-component system. Antimicrob Agents Chemother; 2005 Sep;49(9):3955-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between ceftriaxone resistance of Salmonella enterica serovar Typhimurium and expression of outer membrane proteins OmpW and Ail/OmpX-like protein, which are regulated by BaeR of a two-component system.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Microbiol. 2000 Apr;3(2):165-70 [10745001.001]
  • [Cites] Cell. 1993 Jun 4;73(5):857-71 [8098993.001]
  • [Cites] Eur J Biochem. 2000 May;267(10):2871-81 [10806384.001]
  • [Cites] Semin Cell Dev Biol. 2001 Jun;12(3):215-23 [11428914.001]
  • [Cites] FEMS Microbiol Rev. 2002 Mar;26(1):3-16 [12007640.001]
  • [Cites] J Bacteriol. 2002 Aug;184(15):4161-7 [12107133.001]
  • [Cites] J Bacteriol. 2002 Aug;184(15):4168-76 [12107134.001]
  • [Cites] J Bacteriol. 2003 Mar;185(6):1851-6 [12618449.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Sep;47(9):3030-3 [12937021.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Apr;48(4):1145-50 [15047514.001]
  • [Cites] Int J Antimicrob Agents. 2004 Jun;23(6):547-55 [15194124.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Oct;48(10):3729-35 [15388427.001]
  • [Cites] J Infect Dis. 1987 Nov;156(5):751-7 [2821125.001]
  • [Cites] Science. 1994 Apr 15;264(5157):375-82 [8153624.001]
  • [Cites] Science. 1994 Apr 15;264(5157):382-8 [8153625.001]
  • [Cites] Science. 1994 Apr 15;264(5157):388-93 [8153626.001]
  • [Cites] J Bacteriol. 1998 Sep;180(17):4686-92 [9721312.001]
  • [Cites] Electrophoresis. 1998 Aug;19(11):1941-9 [9740054.001]
  • [Cites] J Bacteriol. 1999 Jun;181(11):3578-81 [10348872.001]
  • [Cites] Antimicrob Agents Chemother. 2000 May;44(5):1223-8 [10770755.001]
  • (PMID = 16127081.001).
  • [ISSN] 0066-4804
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Outer Membrane Proteins; 0 / Cephalosporins; 0 / DNA Transposable Elements; 75J73V1629 / Ceftriaxone
  • [Other-IDs] NLM/ PMC1195446
  •  go-up   go-down


36. Myers-Morales T, Cowan C, Gray ME, Wulff CR, Parker CE, Borchers CH, Straley SC: A surface-focused biotinylation procedure identifies the Yersinia pestis catalase KatY as a membrane-associated but non-surface-located protein. Appl Environ Microbiol; 2007 Sep;73(18):5750-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pla, Lpp, and OmpX (Ail) bound to the NA beads in a non-biotin-specific manner.

  • MedlinePlus Health Information. consumer health - Plague.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Chem. 2000 Mar 15;72(6):1163-8 [10740854.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Feb;78(2):1224-8 [6940138.001]
  • [Cites] Mol Microbiol. 2000 Jul;37(2):239-53 [10931321.001]
  • [Cites] Mol Microbiol. 2001 Jun;40(5):1097-111 [11401715.001]
  • [Cites] Electrophoresis. 2001 May;22(9):1686-96 [11425224.001]
  • [Cites] J Bacteriol. 2002 Feb;184(3):754-9 [11790745.001]
  • [Cites] Protein Sci. 2003 Jun;12(6):1158-68 [12761386.001]
  • [Cites] Cell. 2003 May 30;113(5):587-96 [12787500.001]
  • [Cites] J Bacteriol. 2004 Feb;186(4):949-55 [14761989.001]
  • [Cites] J Bacteriol. 1983 Jan;153(1):241-52 [6294049.001]
  • [Cites] FEBS Lett. 1984 Jan 9;165(2):175-9 [6363121.001]
  • [Cites] J Biol Chem. 1985 Aug 15;260(17):9775-83 [2991262.001]
  • [Cites] J Clin Microbiol. 1986 Sep;24(3):330-2 [3489731.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Mar;86(6):1895-9 [2538820.001]
  • [Cites] Infect Immun. 1990 Aug;58(8):2569-77 [2164509.001]
  • [Cites] Rev Inst Med Trop Sao Paulo. 1990 Mar-Apr;32(2):78-83 [2095628.001]
  • [Cites] FEBS Lett. 1991 Jul 29;286(1-2):79-82 [1677900.001]
  • [Cites] Infect Immun. 1993 Jan;61(1):13-22 [8418035.001]
  • [Cites] Electrophoresis. 1994 May;15(5):594-6 [7523106.001]
  • [Cites] Infect Immun. 1994 Oct;62(10):4526-33 [7927718.001]
  • [Cites] Infect Immun. 1999 Mar;67(3):1359-67 [10024583.001]
  • [Cites] Infect Dis Obstet Gynecol. 1999;7(1-2):58-63 [10231011.001]
  • [Cites] J Bacteriol. 1999 May;181(10):3114-22 [10322012.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Proc R Soc Lond B Biol Sci. 1956 Mar 27;144(918):109-34 [13310588.001]
  • [Cites] Nat Biotechnol. 2004 Nov;22(11):1399-408 [15529165.001]
  • [Cites] Bioinformatics. 2005 Mar 1;21(5):617-23 [15501914.001]
  • [Cites] Infect Immun. 2005 Jun;73(6):3734-9 [15908403.001]
  • [Cites] Methods Mol Biol. 2005;301:117-51 [15917630.001]
  • [Cites] Infect Immun. 2005 Aug;73(8):4743-52 [16040987.001]
  • [Cites] J Bacteriol. 2005 Dec;187(23):8172-80 [16291690.001]
  • [Cites] J Microbiol Methods. 2007 Jan;68(1):26-31 [16857281.001]
  • [Cites] Electrophoresis. 1999 Dec;20(18):3551-67 [10612281.001]
  • [Cites] J Bacteriol. 2000 Jan;182(1):248-51 [10613892.001]
  • [Cites] Infect Immun. 2004 Apr;72(4):2160-9 [15039339.001]
  • [Cites] Vaccine. 2004 Jul 29;22(21-22):2750-6 [15246607.001]
  • [Cites] Int J Med Microbiol. 2004 Jul;294(1):7-14 [15293449.001]
  • [Cites] Microb Ecol. 2004 Apr;47(3):293-9 [15037962.001]
  • [Cites] Proteomics. 2004 Oct;4(10):3021-33 [15378747.001]
  • [Cites] Curr Top Microbiol Immunol. 1972;57:111-58 [4554354.001]
  • [Cites] J Biol Chem. 1972 Jun 25;247(12):3962-72 [4555955.001]
  • [Cites] J Bacteriol. 1973 Sep;115(3):717-22 [4580564.001]
  • [Cites] Anal Biochem. 1977 Oct;82(2):362-71 [20815.001]
  • [Cites] Eur J Biochem. 1981 Jan;113(2):397-403 [6451426.001]
  • [Cites] Eur J Biochem. 2000 May;267(10):2871-81 [10806384.001]
  • (PMID = 17644638.001).
  • [ISSN] 0099-2240
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / L30 AI057175; United States / NIAID NIH HHS / AI / R21 AI061432; United States / NIAID NIH HHS / AI / AI061432; United States / NIAID NIH HHS / AI / UF4 AI057175
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Outer Membrane Proteins; 0 / Membrane Proteins; EC 1.11.1.6 / Catalase
  • [Other-IDs] NLM/ PMC2074897
  •  go-up   go-down


37. Nohra R, Beyeen AD, Guo JP, Khademi M, Sundqvist E, Hedreul MT, Sellebjerg F, Smestad C, Oturai AB, Harbo HF, Wallström E, Hillert J, Alfredsson L, Kockum I, Jagodic M, Lorentzen J, Olsson T: RGMA and IL21R show association with experimental inflammation and multiple sclerosis. Genes Immun; 2010 Jun;11(4):279-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We fine-dissected this region that regulated cytokine production, myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE), anti-MOG antibodies and pristane-induced arthritis (PIA) in advanced intercross lines (AILs).
  • Analysis in the tenth and twelfth generation of AILs resolved the region in two narrow QTL, Eae30 and Eae31.


38. Fredriksson-Ahomaa M, Stolle A, Stephan R: Prevalence of pathogenic Yersinia enterocolitica in pigs slaughtered at a Swiss abattoir. Int J Food Microbiol; 2007 Nov 1;119(3):207-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human yersiniosis is the third most common enteric disease after campylobacteriosis and salmonellosis in many European countries.
  • This work was conducted to study the frequency of ail-positive Y. enterocolitica in pigs slaughtered at a Swiss abattoir.
  • The prevalence rate of ail-positive Y. enterocolitica in pigs at slaughter was 88% and 34% with PCR and culture methods, respectively.
  • The 148 ail-positive isolates from the 72 culture-positive tonsils were bio-and serotyped.
  • However, pig was also shown to be a reservoir for ail-positive Y. enterocolitica belonging to bioserotypes 2/O:5,27 and 2/O:9, which were detected in 8% (6/72) and 1% (1/72) of the culture-positive samples, respectively.
  • Antimicrobial resistance testing of 77 ail-positive Y. enterocolitica isolates from 72 samples studied with disc-diffusion revealed that all strains were sensitive to cefotaxime, chloramphenicol, ciprofloxacin and tetracycline, which are antimicrobial agents used for treatment of human disease.
  • [MeSH-minor] Animals. Anti-Bacterial Agents / pharmacology. Disease Reservoirs / veterinary. Drug Resistance, Bacterial. Electrophoresis, Gel, Pulsed-Field. Food Contamination / analysis. Food Contamination / prevention & control. Genotype. Palatine Tonsil / microbiology. Polymerase Chain Reaction / methods. Prevalence. Risk Assessment. Serotyping. Swine Diseases / drug therapy. Swine Diseases / epidemiology. Swine Diseases / microbiology. Switzerland / epidemiology. Yersinia Infections / drug therapy. Yersinia Infections / epidemiology. Yersinia Infections / microbiology. Yersinia Infections / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17727997.001).
  • [ISSN] 0168-1605
  • [Journal-full-title] International journal of food microbiology
  • [ISO-abbreviation] Int. J. Food Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ail protein, Yersinia enterocolitica; 0 / Anti-Bacterial Agents; 0 / Bacterial Outer Membrane Proteins
  •  go-up   go-down


39. Balakrishna K, Murali HS, Batra HV: Cloning, expression and characterization of attachment-invasion locus protein (Ail) of Yersinia enterocolitica and its utilization in rapid detection by immunoassays. Lett Appl Microbiol; 2010 Feb;50(2):131-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cloning, expression and characterization of attachment-invasion locus protein (Ail) of Yersinia enterocolitica and its utilization in rapid detection by immunoassays.
  • AIMS: Rapid detection of pathogenic Yersinia enterocolitica isolates by using antisera raised against recombinant attachment-invasion locus (Ail) protein.
  • METHODS AND RESULTS: The complete gene (471 bp) encoding for the Ail protein was amplified by PCR and cloned in pQE 30 UA vector.
  • Western blot analysis with the sera raised against recombinant Ail protein exhibited reaction at 17 kDa region of the native Ail protein present in pathogenic Y. enterocolitica standard strains and strains isolated from pork samples suggesting that the antigenicity of recombinant Ail protein was similar to that of native Ail protein.
  • Nonpathogenic Y. enterocolitica and the other species of Yersinia, namely, Y. pseudotuberculosis, Y. intermedia, Y. kristenseni, Y. fredrickseni and also the Enterobacteriaceae organisms tested were not found reacting to polyclonal antisera against this recombinant Ail protein.
  • CONCLUSION: The antibodies raised against recombinant Ail protein could specifically identify pathogenic Y. enterocolitica strains both by indirect plate ELISA and Western blot immunoassay.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20002570.001).
  • [ISSN] 1472-765X
  • [Journal-full-title] Letters in applied microbiology
  • [ISO-abbreviation] Lett. Appl. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ail protein, Yersinia enterocolitica; 0 / Antibodies, Bacterial; 0 / Bacterial Outer Membrane Proteins; 0 / Recombinant Proteins
  •  go-up   go-down


40. Erdur B, Yilmaz S, Oren H, Demircioğlu F, Cakmakç H, Irken G: Evaluating pulmonary complications in childhood acute leukemias. J Pediatr Hematol Oncol; 2008 Jul;30(7):522-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute respiratory distress syndrome, leukostasis, lymphomatoid granulomatosis, pulmonary edema, and pneumothorax were among the noninfectious causes.
  • In conclusion, pulmonary complications are frequent in children with acute leukemia, and early diagnosis and appropriate management are important to avoid mortality owing to pulmonary complications, especially in neutropenic patients receiving induction or consolidation phase of chemotherapy.
  • [MeSH-minor] Acute Disease. Adolescent. Anti-Bacterial Agents / therapeutic use. Antineoplastic Agents / adverse effects. Child. Child, Preschool. Comorbidity. Disseminated Intravascular Coagulation / etiology. Disseminated Intravascular Coagulation / mortality. Female. Humans. Infant. Male. Multiple Organ Failure / etiology. Multiple Organ Failure / mortality. Neutropenia / chemically induced. Neutropenia / complications. Pneumothorax / complications. Pneumothorax / epidemiology. Pulmonary Edema / complications. Pulmonary Edema / epidemiology. Respiration, Artificial / utilization. Respiratory Distress Syndrome, Adult / complications. Respiratory Distress Syndrome, Adult / epidemiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18797199.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


41. Lambertz ST, Nilsson C, Hallanvuo S, Lindblad M: Real-time PCR method for detection of pathogenic Yersinia enterocolitica in food. Appl Environ Microbiol; 2008 Oct;74(19):6060-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The selected primer-probe set was designed to use a 163-bp amplicon from the chromosomally located gene ail (attachment and invasion locus).
  • In addition, the method was tested on naturally contaminated food; in all, 18 out of 125 samples were positive for the ail gene.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Environ Microbiol. 2000 Sep;66(9):3750-5 [10966386.001]
  • [Cites] Int J Food Microbiol. 2008 Mar 31;123(1-2):25-31 [18206260.001]
  • [Cites] Acta Microbiol Pol. 2001;50(1):19-25 [11518390.001]
  • [Cites] J Food Prot. 2001 Sep;64(9):1352-61 [11563512.001]
  • [Cites] Appl Environ Microbiol. 2003 Mar;69(3):1383-90 [12620820.001]
  • [Cites] Int J Food Microbiol. 2003 May 25;83(1):39-48 [12672591.001]
  • [Cites] Clin Microbiol Rev. 2003 Apr;16(2):220-9 [12692095.001]
  • [Cites] J Clin Microbiol. 2003 Dec;41(12):5835 [14662997.001]
  • [Cites] J Clin Microbiol. 2004 May;42(5):1863-8 [15131141.001]
  • [Cites] Appl Environ Microbiol. 2004 Jun;70(6):3588-92 [15184161.001]
  • [Cites] J Clin Microbiol. 1986 Jul;24(1):116-20 [3722357.001]
  • [Cites] Infect Immun. 1989 Jan;57(1):121-31 [2642465.001]
  • [Cites] Appl Environ Microbiol. 1991 Feb;57(2):389-94 [2014988.001]
  • [Cites] Int J Food Microbiol. 1991 Jan;12(1):53-65 [2018706.001]
  • [Cites] J Bacteriol. 1992 Feb;174(4):1360-9 [1370953.001]
  • [Cites] Appl Environ Microbiol. 1993 Sep;59(9):2938-44 [8215366.001]
  • [Cites] Appl Environ Microbiol. 1997 Dec;63(12):4952-5 [9406416.001]
  • [Cites] Appl Environ Microbiol. 1998 May;64(5):1812-5 [9572955.001]
  • [Cites] Int J Food Microbiol. 1998 Dec 8;45(2):93-105 [9924940.001]
  • [Cites] Appl Environ Microbiol. 2004 Dec;70(12):7046-52 [15574899.001]
  • [Cites] Int J Food Microbiol. 2005 Nov 15;105(1):71-82 [16085330.001]
  • [Cites] J Food Prot. 2006 Aug;69(8):1983-5 [16924928.001]
  • [Cites] J Food Prot. 2007 Feb;70(2):335-40 [17340866.001]
  • [Cites] Appl Environ Microbiol. 2007 Mar;73(6):1892-8 [17259359.001]
  • [Cites] Appl Environ Microbiol. 2000 Sep;66(9):4131-5 [10966441.001]
  • (PMID = 18708521.001).
  • [ISSN] 1098-5336
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ail protein, Yersinia enterocolitica; 0 / Bacterial Outer Membrane Proteins; 0 / DNA Primers; 0 / DNA, Bacterial
  • [Other-IDs] NLM/ PMC2565965
  •  go-up   go-down


42. Weintraub WS, Mahoney EM, Lamy A, Culler S, Yuan Y, Caro J, Gabriel S, Yusuf S, CURE Study Investigators: Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol; 2005 Mar 15;45(6):838-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Excluding clopidogrel costs, average costs of hospitalizations alone were 325 dollars less for the clopidogrel arm (95% confidence interval -722 dollars to 45 dollars) using diagnosis-related group-based Medicare reimbursement rates.
  • The incremental cost-effectiveness ratio (ICER) on the basis of the Framingham Heart Study was 6,318 dollars per life-year gained (LYG) with clopidogrel, with 94% of bootstrap-derived ICER estimates <50,000 dollars/LYG; based on Saskatchewan, the ICER was 6,475 dollars/LYG with 98% of estimates <50,000 dollars.
  • [MeSH-major] Coronary Disease / drug therapy. Coronary Disease / economics. Electrocardiography. Myocardial Infarction / drug therapy. Myocardial Infarction / economics. Platelet Aggregation Inhibitors / economics. Platelet Aggregation Inhibitors / therapeutic use. Ticlopidine / analogs & derivatives. Ticlopidine / economics. Ticlopidine / therapeutic use
  • [MeSH-minor] Acute Disease. Aged. Cost-Benefit Analysis / economics. Cost-Benefit Analysis / statistics & numerical data. Female. Follow-Up Studies. Humans. Length of Stay / economics. Life Expectancy. Male. Medicare / economics. Middle Aged. Patient Admission / economics. Patient Admission / statistics & numerical data. Quality-Adjusted Life Years. Sensitivity and Specificity. Syndrome. Time. Treatment Outcome. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CLOPIDOGREL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Evid Based Cardiovasc Med. 2005 Sep;9(3):221-4 [16380037.001]
  • (PMID = 15766816.001).
  • [ISSN] 0735-1097
  • [Journal-full-title] Journal of the American College of Cardiology
  • [ISO-abbreviation] J. Am. Coll. Cardiol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors; A74586SNO7 / clopidogrel; OM90ZUW7M1 / Ticlopidine
  •  go-up   go-down


43. Eroshenko GA, Odinokov GN, Kukleva LM, Krasnov IaM, Kutyrev VV: [Sequence analysis of the yadA, inv, and ail genes and their expression in the main and nonmain Yersinia pestis subspecies and Yersinia pseudotuberculosis]. Genetika; 2010 Jun;46(6):734-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sequence analysis of the yadA, inv, and ail genes and their expression in the main and nonmain Yersinia pestis subspecies and Yersinia pseudotuberculosis].
  • The nucleotide sequences of the inv, yadA, and ail adhesin-invasin genes were analyzed in 24 strains of the main and nonmain Yersinia pestis subspecies, which were isolated from natural plague foci in Russia and neighbor countries, and ten Y. pseudotuberculosis strains.
  • All of the five plague agent subspecies (main, caucasica, altaica, ulegeica, and hissarica) had the inv and yadA genes altered by insertion of the IS element and a single nucleotide deletion, respectively, as was earlier observed for the Y. pestis strains KIM and CO92.
  • The ail gene of the main and ulegeica subspecies had a missense mutation, which replaced Val138 with Phe in the Ail protein.
  • The strains of the caucasica subspecies had an AGT insertion in the ail gene, resulting in Ser148 insertion in the polypeptide chain.
  • The changes in the ail sequence probably exerted no effect on ail expression, since the strains of all subspecies were resistant to blood serum complement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20734763.001).
  • [ISSN] 0016-6758
  • [Journal-full-title] Genetika
  • [ISO-abbreviation] Genetika
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Ail protein, Yersinia pestis; 0 / Bacterial Outer Membrane Proteins; 0 / DNA Transposable Elements; 0 / Virulence Factors; 0 / YadA protein, Yersinia; 114073-91-5 / invasin, Yersinia
  •  go-up   go-down


44. Lee Clark D, Peters SE: Isometric contractile properties of sexually dimorphic forelimb muscles in the marine toad Bufo marinus Linnaeus 1758: functional analysis and implications for amplexus. J Exp Biol; 2006 Sep;209(Pt 17):3448-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We extended this study to a distantly related species, Bufo marinus Linnaeus 1758, by testing the isometric contractile properties of three muscles, abductor indicus longus (AIL), and flexor carpi radialis (FCR) (both dimorphic muscles), and extensor carpi ulnaris (ECU) (non-dimorphic control).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916980.001).
  • [ISSN] 0022-0949
  • [Journal-full-title] The Journal of experimental biology
  • [ISO-abbreviation] J. Exp. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


45. Norum J, Hagen AI, Maehle L, Apold J, Burn J, Møller P: Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis. Eur J Cancer; 2008 May;44(7):963-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The additional health care cost per mutation carrier undergoing PBSO and PBM was euro 15,784, and 6.4 discounted life years gained (LYG) was indicated (PBSO alone with 100% acceptance 3.1 LYG).
  • The additional cost per LYG was euro 1973 (PBSO alone euro 1749/LYG).
  • Including all resource use, the figure was a cost of euro 496 and euro 1284 per LYG, respectively.


46. Bikilla AD, Jerene D, Robberstad B, Lindtjørn B: Cost-effectiveness of anti-retroviral therapy at a district hospital in southern Ethiopia. Cost Eff Resour Alloc; 2009;7:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We measured the health effect as life years gained (LYG) for patients receiving ART compared with those not receiving such treatment.
  • FINDINGS: ART yielded an undiscounted 9.4 years expected survival, and resulted in 7.1 extra LYG compared to patients not receiving ART.
  • The lifetime incremental cost is US$2,215 and the undiscounted incremental cost per LYG is US$314.
  • When discounted at 3%, the additional LYG decreases to 5.5 years and the incremental cost per LYG increases to US$325.
  • CONCLUSION: The undiscounted and discounted incremental costs per LYG from introducing ART were less than the per capita GDP threshold at the base year.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS Med. 2006 Jan;3(1):e4 [16318413.001]
  • [Cites] MedGenMed. 2005;7(3):66 [16369292.001]
  • [Cites] BMJ. 2005 Dec 17;331(7530):1431-7 [16282380.001]
  • [Cites] AIDS. 2006 Jan 2;20(1):67-71 [16327321.001]
  • [Cites] Clin Infect Dis. 2005 Aug 1;41(3):376-85 [16007536.001]
  • [Cites] J Med Virol. 2005 Aug;76(4):441-6 [15977249.001]
  • [Cites] AIDS Res Ther. 2006;3:10 [16600050.001]
  • [Cites] Stat Med. 1999 Dec 15;18(23):3235-44 [10602148.001]
  • [Cites] Cost Eff Resour Alloc. 2009;7:6 [19364399.001]
  • [Cites] PLoS Med. 2009 Apr 28;6(4):e1000066 [19399157.001]
  • [Cites] Cost Eff Resour Alloc. 2006;4:20 [17147833.001]
  • [Cites] Lancet. 2006 Nov 4;368(9547):1575-80 [17084757.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1141-53 [16971720.001]
  • [Cites] Med Decis Making. 1993 Oct-Dec;13(4):322-38 [8246705.001]
  • (PMID = 19615069.001).
  • [ISSN] 1478-7547
  • [Journal-full-title] Cost effectiveness and resource allocation : C/E
  • [ISO-abbreviation] Cost Eff Resour Alloc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2724492
  •  go-up   go-down


47. Fawcett GL, Jarvis JP, Roseman CC, Wang B, Wolf JB, Cheverud JM: Fine-mapping of obesity-related quantitative trait loci in an F9/10 advanced intercross line. Obesity (Silver Spring); 2010 Jul;18(7):1383-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although there has been significant progress in characterizing genes in many pathways contributing to metabolic disease, knowledge about the relationships of these genes to each other and their joint effects upon obesity lags behind.
  • The LG,SM advanced intercross line (AIL) model of obesity has been used to characterize over 70 loci involved in fatpad weight, body weight, and organ weights.
  • [MeSH-minor] Animals. Breeding / methods. Disease Models, Animal. Epistasis, Genetic / genetics. Female. Genome. Hybridization, Genetic. Male. Mice. Sex Characteristics

  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genetics. 2008 Apr;178(4):2275-88 [18430949.001]
  • [Cites] Diabetologia. 1997 Aug;40(8):976-9 [9267995.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jun;93(6):2027-34 [18539769.001]
  • [Cites] J Bone Miner Res. 2008 Jun;23(6):887-95 [18435578.001]
  • [Cites] Int J Obes (Lond). 2008 Jul;32(7):1180-9 [18414419.001]
  • [Cites] Obesity (Silver Spring). 2008 Aug;16(8):1861-8 [18551125.001]
  • [Cites] Physiol Genomics. 2009 Jan 8;36(2):114-26 [18984673.001]
  • [Cites] Mamm Genome. 2009 Apr;20(4):224-35 [19306044.001]
  • [Cites] J Evol Biol. 2009 Aug;22(8):1658-68 [19523039.001]
  • [Cites] J Lipid Res. 2010 May;51(5):907-13 [20388922.001]
  • [Cites] Genet Res. 1999 Dec;74(3):313-22 [10689807.001]
  • [Cites] Nat Genet. 2000 Oct;26(2):163-75 [11017071.001]
  • [Cites] Mamm Genome. 2001 Jan;12(1):3-12 [11178736.001]
  • [Cites] Heredity (Edinb). 2001 Jul;87(Pt 1):52-8 [11678987.001]
  • [Cites] Bioinformatics. 2003 May 1;19(7):889-90 [12724300.001]
  • [Cites] Obes Res. 2003 Nov;11(11):1400-10 [14627762.001]
  • [Cites] Diabetes. 2004 Dec;53(12):3328-36 [15561968.001]
  • [Cites] Diabetes. 2005 Apr;54(4):1207-13 [15793263.001]
  • [Cites] Physiol Genomics. 2005 May 11;21(3):411-22 [15769905.001]
  • [Cites] Diabetes. 2005 Jun;54(6):1863-72 [15919810.001]
  • [Cites] Heredity (Edinb). 2005 Sep;95(3):221-7 [16077740.001]
  • [Cites] Genet Res. 2005 Jun;85(3):211-22 [16174340.001]
  • [Cites] Mamm Genome. 2005 Oct;16(10):764-74 [16261418.001]
  • [Cites] Mamm Genome. 2006 Jan;17(1):22-36 [16416088.001]
  • [Cites] Genet Res. 2006 Feb;87(1):45-60 [16545150.001]
  • [Cites] Science. 2006 Apr 14;312(5771):279-83 [16614226.001]
  • [Cites] Mamm Genome. 2006 May;17(5):417-29 [16688532.001]
  • [Cites] Heredity (Edinb). 1992 Oct;69(4):315-24 [16718932.001]
  • [Cites] Obesity (Silver Spring). 2006 Apr;14(4):529-644 [16741264.001]
  • [Cites] Mamm Genome. 2006 Jun;17(6):526-37 [16783635.001]
  • [Cites] Genetics. 2007 Jan;175(1):349-60 [17110492.001]
  • [Cites] Science. 2007 May 11;316(5826):889-94 [17434869.001]
  • [Cites] Genet Res. 2007 Feb;89(1):47-59 [17517159.001]
  • [Cites] Hum Mol Genet. 2007 Dec 15;16(24):3017-26 [17855449.001]
  • [Cites] Nature. 2008 Mar 27;452(7186):470-2 [18368117.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2008 Apr;294(4):R1185-96 [18256137.001]
  • [Cites] PLoS Genet. 2007 Jul;3(7):e115 [17658951.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1762-72 [14660752.001]
  • [Cites] PLoS Biol. 2003 Dec;1(3):E68 [14691540.001]
  • [Cites] Genetics. 2004 May;167(1):399-409 [15166164.001]
  • [Cites] J Lipid Res. 2004 Nov;45(11):2063-70 [15314098.001]
  • [Cites] Genetics. 1992 Dec;132(4):1211-22 [1459438.001]
  • [Cites] Genetics. 1995 Mar;139(3):1455-61 [7768453.001]
  • [Cites] Nat Genet. 1995 Nov;11(3):241-7 [7581446.001]
  • [Cites] Genome Res. 1996 May;6(5):431-8 [8743992.001]
  • [Cites] Genome Res. 1995 Aug;5(1):5-12 [8717050.001]
  • [Cites] PLoS Genet. 2008 Jun;4(6):e1000091 [18535661.001]
  • (PMID = 19910941.001).
  • [ISSN] 1930-739X
  • [Journal-full-title] Obesity (Silver Spring, Md.)
  • [ISO-abbreviation] Obesity (Silver Spring)
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / R24 RR015116; United States / NIDDK NIH HHS / DK / P30 DK056341-08; United States / NIDDK NIH HHS / DK / P30 DK056341; United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/C/516936; United States / NIDDK NIH HHS / DK / DK055736; United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/C516936/1; United States / NIDDK NIH HHS / DK / R01 DK055736-07; United States / NIDDK NIH HHS / DK / R01 DK055736; United States / NIDDK NIH HHS / DK / R56 DK055736; United States / NCRR NIH HHS / RR / R24 RR015116-07; United States / NIDDK NIH HHS / DK / P30 DK056341-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS487377; NLM/ PMC3848327
  •  go-up   go-down


48. Benamore RE, Weisbrod GL, Hwang DM, Bailey DJ, Pierre AF, Lazar NM, Maimon N: Reversed halo sign in lymphomatoid granulomatosis. Br J Radiol; 2007 Aug;80(956):e162-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversed halo sign in lymphomatoid granulomatosis.
  • Lymphomatoid granulomatosis is a rare lymphoproliferative disorder which affects extranodal sites, most commonly lung.
  • We describe a case of histologically proven lymphomatoid granulomatosis in a patient who presented initially with the more typical nodular opacities, which subsequently progressed into the reversed halo sign.
  • [MeSH-major] Lung Diseases / radiography. Lymphomatoid Granulomatosis / radiography

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Radiol. 2007 Oct;80(958):849-50 [17959924.001]
  • (PMID = 17762047.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Miyashita T, Yoshioka K, Nakamura T, Kubo Y, Inoue T, Morikawa T, Ishii K, Yamagami K: A case of lymphomatoid granulomatosis-like lung lesions with abundant infiltrating IgG4-positive plasma cells whose serum IgG4 levels became high following the start of corticosteroid therapy. Intern Med; 2010;49(18):2007-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of lymphomatoid granulomatosis-like lung lesions with abundant infiltrating IgG4-positive plasma cells whose serum IgG4 levels became high following the start of corticosteroid therapy.
  • We initially suspected lymphomatoid granulomatosis, but Epstein Barr virus-encoded small RNA was negative.
  • He was diagnosed with IgG4-related sclerosing disease even though serum IgG4 levels were not elevated (45.7 mg/dL).
  • Seronegative IgG4-related sclerosing disease should be considered when patients present with such symptoms and treatment responses, and the secretion of IgG4 might be blocked by its active synthesis.
  • [MeSH-major] Immunoglobulin G / blood. Lung Neoplasms / chemically induced. Lymphomatoid Granulomatosis / chemically induced. Plasma Cells / pathology. Prednisolone / adverse effects

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20847508.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin G; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


50. Oliva J, López-Bastida J, Moreno SG, Mata P, Alonso R: [Cost-effectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia]. Rev Esp Cardiol; 2009 Jan;62(1):57-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Análisis coste-efectividad de un programa de cribado genético en familiares directos de pacientes con hipercolesterolemia familiar en España.
  • In the cost-effectiveness analysis, the number of life-years gained (LYG) was regarded as the health outcome and the costs of screening, statin treatment, specialist consultations and hospital visits were all included.
  • RESULTS: In the base case, the incremental cost of the screening program for close relatives was 3423 euros per LYG.
  • The screening program was found to be better than the alternative considered at a probability level of 95% if the acceptable level of health-care costs was at least 7400 euros per LYG.


51. Brignole C, Marimpietri D, Pastorino F, Di Paolo D, Pagnan G, Loi M, Piccardi F, Cilli M, Tradori-Cappai A, Arrigoni G, Pistoia V, Ponzoni M: Anti-IL-10R antibody improves the therapeutic efficacy of targeted liposomal oligonucleotides. J Control Release; 2009 Sep 1;138(2):122-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In principle, combination of TL-asCpG and antibodies against IL-10 receptor (aIL-10R) could prolong immune system activation, leading to better therapeutic results.
  • The addition of aIL-10R to TL-asCpG in the 4-h protocol significantly increased the percentage of long term survivors compared to TL-asCpG only.
  • TL-asCpG plus aIL-10R treatment was significantly superior to TL-asCpG alone also for the 24-h protocol.
  • These results support the feasibility of a clinical trial with TL-asCpG and aIL-10R in advanced NB patients.

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19427884.001).
  • [ISSN] 1873-4995
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gangliosides; 0 / Liposomes; 0 / Oligonucleotides, Antisense; 0 / Proto-Oncogene Proteins c-myb; 0 / Receptors, Interleukin-10; 130068-27-8 / Interleukin-10; 65988-71-8 / ganglioside, GD2
  •  go-up   go-down


52. Lyseng-Williamson KA, Plosker GL: Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes. Pharmacoeconomics; 2006;24(7):709-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clopidogrel plus aspirin in patients with ACS reduced the incremental cost per cardiovascular event prevented and/or life-year gained (LYG) relative to aspirin alone in analyses using within-trial data (including longer-term analyses incorporating life-expectancy estimates) from the CURE or PCI-CURE studies.
  • In Markov models of cost effectiveness with a lifetime horizon from a healthcare payer perspective based on the CURE trial, relative to aspirin alone, clopidogrel plus aspirin for 1 year was predicted to have incremental costs per LYG of 8132Euro in Spain (2003 values) and 1365Euro in Sweden (2000 values).
  • In similar Swedish analyses from a healthcare payer perspective, clopidogrel plus aspirin for 1 year was predicted to have incremental costs per LYG of 10,993Euro (2004 values) relative to aspirin alone based on data from the PCI-CURE substudy.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / economics. Aspirin / economics. Coronary Disease / drug therapy. Cost-Benefit Analysis. Platelet Aggregation Inhibitors / economics. Prescription Fees / statistics & numerical data. Ticlopidine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. CLOPIDOGREL .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Heart J. 2000 Sep;21(17):1440-9 [10952836.001]
  • [Cites] Eur Heart J. 2003 Oct;24(20):1815-23 [14563340.001]
  • [Cites] Value Health. 2004 Jan-Feb;7(1):52-60 [14720130.001]
  • [Cites] Drugs Aging. 2002;19(9):633-46 [12381234.001]
  • [Cites] Eur J Health Econ. 2007 Mar;8(1):51-7 [17186199.001]
  • [Cites] Circulation. 2004 Sep 7;110(10):1202-8 [15313956.001]
  • [Cites] N Engl J Med. 2001 Aug 16;345(7):494-502 [11519503.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):1980-7 [15388526.001]
  • [Cites] Eur Heart J. 2006 Mar;27(6):671-8 [16423872.001]
  • [Cites] Circulation. 2002 Sep 24;106(13):1622-6 [12270853.001]
  • [Cites] J Intern Med. 2004 May;255(5):562-70 [15078498.001]
  • [Cites] Eur Heart J. 2002 Aug;23(15):1177-89 [12127920.001]
  • [Cites] Am Heart J. 2001 May;141(5):727-34 [11320359.001]
  • [Cites] Heart. 2005 Sep;91(9):1135-40 [16103539.001]
  • [Cites] JAMA. 2002 Nov 20;288(19):2411-20 [12435254.001]
  • [Cites] Circulation. 2003 Oct 7;108(14):1682-7 [14504182.001]
  • [Cites] Health Technol Assess. 2004 Oct;8(40):iii-iv, xv-xvi, 1-141 [15461878.001]
  • [Cites] Lancet. 2005 Nov 5;366(9497):1607-21 [16271642.001]
  • [Cites] Circulation. 2000 Feb 1;101(4):366-71 [10653826.001]
  • [Cites] Ann Intern Med. 2005 Feb 15;142(4):251-9 [15710958.001]
  • [Cites] Lancet. 2001 Aug 18;358(9281):527-33 [11520521.001]
  • [Cites] Aust Fam Physician. 2001 Oct;30(10):959-63 [11706604.001]
  • [Cites] Am J Cardiovasc Drugs. 2001;1(6):467-74; discussion 475-6 [14728005.001]
  • [Cites] Eur J Cardiovasc Prev Rehabil. 2004 Dec;11(6):460-5 [15580055.001]
  • [Cites] Eur Heart J. 2004 Nov;25(22):2013-8 [15541837.001]
  • [Cites] Circulation. 2002 Oct 1;106(14 ):1893-900 [12356647.001]
  • [Cites] Clin Ther. 2005 Jan;27(1):100-10 [15763611.001]
  • [Cites] JAMA. 2000 Dec 6;284(21):2748-54 [11105180.001]
  • [Cites] Rev Esp Cardiol. 2005 Dec;58(12):1385-95 [16371197.001]
  • [Cites] Am Heart J. 2005 Dec;150(6):1177-84 [16338255.001]
  • [Cites] J Am Coll Cardiol. 2005 Mar 15;45(6):838-45 [15766816.001]
  • [Cites] Eur Heart J. 2002 Dec;23(23):1809-40 [12503543.001]
  • [Cites] Eur Heart J. 2004 Apr;25(8):663-70 [15084371.001]
  • [Cites] Am Heart J. 2006 Jan;151(1):219-27 [16368322.001]
  • [Cites] N Engl J Med. 2005 Mar 24;352(12):1179-89 [15758000.001]
  • [Cites] JAMA. 2002 Oct 16;288(15):1851-8 [12377083.001]
  • [Cites] J Am Coll Cardiol. 2005 Jan 18;45(2):246-51 [15653023.001]
  • [Cites] N Engl J Med. 1992 Jul 2;327(1):7-13 [1598117.001]
  • [Cites] N Engl J Med. 1997 Jan 30;336(5):332-6 [9011785.001]
  • [Cites] Int J Cardiol. 2006 May 24;109(3):307-16 [16026869.001]
  • [Cites] Chest. 2004 Aug;126(2):461-9 [15302732.001]
  • (PMID = 16802846.001).
  • [ISSN] 1170-7690
  • [Journal-full-title] PharmacoEconomics
  • [ISO-abbreviation] Pharmacoeconomics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Platelet Aggregation Inhibitors; A74586SNO7 / clopidogrel; OM90ZUW7M1 / Ticlopidine; R16CO5Y76E / Aspirin
  • [Number-of-references] 54
  •  go-up   go-down


53. Gustafson A, Khavjou O, Stearns SC, Keyserling TC, Gizlice Z, Lindsley S, Bramble K, Garcia B, Johnston L, Will J, Poindexter P, Ammerman AS, Samuel-Hodge CD: Cost-effectiveness of a behavioral weight loss intervention for low-income women: the Weight-Wise Program. Prev Med; 2009 Nov;49(5):390-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Women were randomized to one of two arms-special intervention (n=72) and a wait-listed control group (n=71).
  • Cost-effectiveness measures calculated life years gained (LYG) from changes in weight, based on excess years life lost (YLL) algorithm.

  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Weight Control.
  • MedlinePlus Health Information. consumer health - Women's Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19747937.001).
  • [ISSN] 1096-0260
  • [Journal-full-title] Preventive medicine
  • [ISO-abbreviation] Prev Med
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK56350; United States / PHS HHS / / U48/CCU422824-04
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


54. Head JE, Shen D, Santiago-Maysonet M, Bishop RJ, Chan CC: Ocular pathology of uncommon hematologic malignancies: a case series. J Med Case Rep; 2007;1:158
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, reports of ocular involvement in such diseases as lymphomatoid granulomatosis and chronic myelomonocytic leukemia are uncommon.
  • CASE PRESENTATION: In the first case, a 54-year-old man with a previous diagnosis of lymphomatoid granulomatosis presented with a new-onset conjunctival lesion while his systemic disease was thought to be in remission.
  • A biopsy was taken that revealed heavy infiltrates of B and T cells at the site of the lesion.
  • Molecular analysis confirmed that these cells were positive for both Epstein-Barr viral DNA and immunoglobulin heavy chain gene rearrangement, consistent with a manifestation of his systemic disease.
  • Post-mortem studies revealed the presence of atypical monocytes in the choroidal and subretinal spaces, consistent with his previous diagnosis.
  • We herein emphasize novel findings in each case, including conjunctival involvement as the first sign of recurrent lymphomatoid granulomatosis and the combination of subretinal and choroidal myelomonocytic leukemic infiltration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmologica. 1988;196(3):161-6 [3405587.001]
  • [Cites] Hum Pathol. 1972 Dec;3(4):457-558 [4638966.001]
  • [Cites] Arch Dermatol. 1996 Dec;132(12):1464-70 [8961876.001]
  • [Cites] Nat Rev Cancer. 2007 Feb;7(2):118-29 [17251918.001]
  • [Cites] Ophthalmologica. 2003 Nov-Dec;217(6):441-5 [14573980.001]
  • [Cites] Trans Am Ophthalmol Soc. 2003;101:275-92 [14971583.001]
  • [Cites] J Neuroophthalmol. 1998 Jun;18(2):150-2 [9621274.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] Eye (Lond). 2002 Sep;16(5):651-3 [12194088.001]
  • [Cites] Jpn J Ophthalmol. 2005 Sep-Oct;49(5):377-83 [16187037.001]
  • (PMID = 18045486.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2211492
  •  go-up   go-down


55. de Vries R, Klok RM, Brouwers JR, Postma MJ: Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: the impact of varying the discount rate for health. Vaccine; 2009 Feb 5;27(6):846-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When applying the current discount rate of 1.5% for health, the expected cost-effectiveness of HP vaccination is estimated below the informal Dutch threshold of euro 20,000/LYG when the HP prevalence is assumed > or =20% in the Dutch population.


56. Galbraith RM, Hawkins RE, Holmboe ES: Making self-assessment more effective. J Contin Educ Health Prof; 2008;28(1):20-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although these enhancements individually may not cure all of what ails self-assessment, they might ensure greater effectiveness for the purposes of lifelong learning.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18366125.001).
  • [ISSN] 0894-1912
  • [Journal-full-title] The Journal of continuing education in the health professions
  • [ISO-abbreviation] J Contin Educ Health Prof
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Katzenstein AL, Doxtader E, Narendra S: Lymphomatoid granulomatosis: insights gained over 4 decades. Am J Surg Pathol; 2010 Dec;34(12):e35-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid granulomatosis: insights gained over 4 decades.
  • Lymphomatoid granulomatosis is a rare lymphoproliferative disease involving predominantly the lung, and there is uncertainty about its relationship to lymphoma.
  • Morphologically, there is overlap in grades 2 and 3 with variants of large B-cell lymphoma, and many such cases show evidence of monoclonality by polymerase chain reaction.
  • It is suggested that lymphoma (T-cell rich large B-cell or diffuse large B-cell) be diagnosed in addition to lymphomatoid granulomatosis in grades 2 and 3 to appropriately communicate the nature of the disease to clinicians.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Lung Neoplasms / pathology. Lymphoma / pathology. Lymphomatoid Granulomatosis / pathology


58. Frías C, Cortés J, Seguí MÁ, Oyagüez I, Casado MÁ: Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain. Clin Transl Oncol; 2010 Oct;12(10):692-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cost and benefits [life-years gained (LYG) and quality-adjusted life years (QALY)] were discounted at 3%.
  • RESULTS: Docetaxel yields higher health benefits (1.83 LYG; 1.08 QALY) than paclitaxel (1.46 LYG; 0.84 QALY).
  • Incremental cost-effectiveness ratio (ICER) of docetaxel versus paclitaxel was €190/LYG and €295/QALY.
  • [MeSH-minor] Anthracyclines / therapeutic use. Clinical Trials, Phase III as Topic. Cost-Benefit Analysis. Disease Progression. Female. Humans. Markov Chains. Quality-Adjusted Life Years. Randomized Controlled Trials as Topic. Salvage Therapy / economics. Spain

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4216-23 [11709565.001]
  • [Cites] Eur J Cancer. 2008 Oct;44(15):2218-25 [18722111.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5542-51 [16110015.001]
  • [Cites] Expert Opin Pharmacother. 2009 Feb;10(2):283-90 [19236199.001]
  • [Cites] Pharmacoeconomics. 1996;9 Suppl 2:8-22 [10163967.001]
  • [Cites] Oncology (Williston Park). 2008 May;22(6):614-23; discussion 623, 627-9 [18561551.001]
  • [Cites] Br J Cancer. 2006 Sep 18;95(6):683-90 [16967055.001]
  • [Cites] Drugs. 2000 Mar;59(3):621-51 [10776837.001]
  • [Cites] Health Technol Assess. 1999;3(2):1-134 [10448202.001]
  • [Cites] Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003366 [15846659.001]
  • [Cites] Clin Transl Oncol. 2006 Jul;8(7):508-18 [16870541.001]
  • [Cites] Clin Breast Cancer. 2008 Jun;8(3):224-33 [18650152.001]
  • [Cites] Med Decis Making. 2002 Jul-Aug;22(4):290-308 [12150595.001]
  • [Cites] Ann Intern Med. 1997 Oct 15;127(8 Pt 2):752-6 [9382393.001]
  • [Cites] Oncologist. 2005 Oct;10(9):665-85 [16249346.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):77-83 [15188011.001]
  • [Cites] Ann Oncol. 2008 Mar;19(3):461-4 [18006892.001]
  • [Cites] Gac Sanit. 2002 Jul-Aug;16(4):334-43 [12113733.001]
  • [Cites] Farm Hosp. 2008 May-Jun;32(3):139-47 [18840343.001]
  • [Cites] Anticancer Drugs. 1998 Nov;9(10):899-907 [9890701.001]
  • [Cites] Pharmacoeconomics. 2001;19(11):1091-102 [11735676.001]
  • [Cites] Expert Opin Pharmacother. 2008 Oct;9(15):2603-16 [18803448.001]
  • [Cites] N Engl J Med. 2008 Apr 17;358(16):1663-71 [18420499.001]
  • [Cites] Pharmacoeconomics. 2009;27(10 ):847-59 [19803539.001]
  • [Cites] Value Health. 2007 Sep-Oct;10(5):326-35 [17888097.001]
  • [Cites] Am J Health Syst Pharm. 1997 Dec 15;54(24 Suppl 2):S11-5 [9435927.001]
  • [Cites] Med Clin (Barc). 2008 Oct;131 Suppl 1:50-2 [19080815.001]
  • [Cites] Pharmacoeconomics. 1996 Nov;10(5):504-21 [10169397.001]
  • [Cites] Pharmacoeconomics. 1998 Oct;14(4):447-59 [10344911.001]
  • [Cites] Clin Transl Oncol. 2009 Jan;11(1):41-7 [19155203.001]
  • [Cites] Drugs. 2005;65(17):2513-31 [16296875.001]
  • [Cites] Oncologist. 2005;10 Suppl 3:20-9 [16368868.001]
  • [Cites] Farm Hosp. 2004 Jul-Aug;28(4):231-42 [15369433.001]
  • [Cites] Anticancer Drugs. 2007 Aug;18(7):843-59 [17581310.001]
  • [Cites] Value Health. 2005 Jan-Feb;8(1):1-2 [15841888.001]
  • [Cites] Pharmacoeconomics. 1998 Apr;13(4):397-409 [10178664.001]
  • [Cites] Semin Oncol. 2001 Apr;28(2 Suppl 7):15-7 [11372047.001]
  • (PMID = 20947484.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


59. Chamiot B, Rizzi C, Gaillon L, Sirieix-Plénet J, Lelièvre J: Redox-switched amphiphilic ionic liquid behavior in aqueous solution. Langmuir; 2009 Feb 3;25(3):1311-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A new redox amphiphilic ionic liquid (AIL) containing ferrocene as a redox-active group was synthesized, 1-(11-ferrocenylundecyl)-3-methylimidazolium bromide (Fc11MIm+).
  • Adsorption and aggregation of both reduced and oxidized forms of this ferrocenated AIL in aqueous solution were studied by surface tension measurements.
  • The micellization was favored for the reduced ferrocenated AIL (Fc11MIm+) as compared with the oxidized ferrocenated AIL (Fc+11MIm+).
  • This corroborated the formation of an expanded monolayer of redox active AIL at the interface.
  • The electrochemical behavior of redox active AIL was investigated.
  • Below the cmc, the electrochemical reaction was dominated by ferrocenated AIL adsorbed onto the electrode surface; then above the cmc, it was controlled by the Fc11MIm+ diffusing to the electrode.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19125689.001).
  • [ISSN] 0743-7463
  • [Journal-full-title] Langmuir : the ACS journal of surfaces and colloids
  • [ISO-abbreviation] Langmuir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Best drugs for what ails you: the brands to buy--and those to skip. Consum Rep; 2009 Sep;74(9):14-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Best drugs for what ails you: the brands to buy--and those to skip.

  • MedlinePlus Health Information. consumer health - Allergy.
  • MedlinePlus Health Information. consumer health - Common Cold.
  • MedlinePlus Health Information. consumer health - Cough.
  • MedlinePlus Health Information. consumer health - Flu.
  • MedlinePlus Health Information. consumer health - Flu Shot.
  • MedlinePlus Health Information. consumer health - Over-the-Counter Medicines.
  • MedlinePlus Health Information. consumer health - Sore Throat.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • Hazardous Substances Data Bank. DEXTROMETHORPHAN .
  • Hazardous Substances Data Bank. CHLORPHENIRAMINE .
  • Hazardous Substances Data Bank. OXYMETAZOLINE .
  • Hazardous Substances Data Bank. IBUPROFEN .
  • Hazardous Substances Data Bank. GLYCERIN .
  • Hazardous Substances Data Bank. DIPHENHYDRAMINE .
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • Hazardous Substances Data Bank. LORATADINE .
  • Hazardous Substances Data Bank. Cetirizine .
  • Hazardous Substances Data Bank. PSEUDOEPHEDRINE .
  • Hazardous Substances Data Bank. GUAIFENESIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19821542.001).
  • [ISSN] 0010-7174
  • [Journal-full-title] Consumer reports
  • [ISO-abbreviation] Consum Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anesthetics, Local; 0 / Expectorants; 0 / Histamine Antagonists; 0 / Influenza Vaccines; 0 / Nonprescription Drugs; 0 / Propiophenones; 078A24Q30O / dyclonine; 362O9ITL9D / Acetaminophen; 3U6IO1965U / Chlorpheniramine; 451W47IQ8X / Sodium Chloride; 495W7451VQ / Guaifenesin; 7355X3ROTS / Dextromethorphan; 7AJO3BO7QN / Loratadine; 7CUC9DDI9F / Pseudoephedrine; 8GTS82S83M / Diphenhydramine; 8VLN5B44ZY / Oxymetazoline; PDC6A3C0OX / Glycerol; WK2XYI10QM / Ibuprofen; YO7261ME24 / Cetirizine
  •  go-up   go-down


61. Lioi L, Galasso I, Lanave C, Daminati MG, Bollini R, Sparvoli F: Evolutionary analysis of the APA genes in the Phaseolus genus: wild and cultivated bean species as sources of lectin-related resistance factors? Theor Appl Genet; 2007 Nov;115(7):959-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition P. augusti, P. maculatus, P. microcarpus, and P. oligospermus showed the presence of the lectin-related alpha-amylase inhibitor-like (AIL) genes and alpha-AI activity.
  • The finding of detectable alpha-AI activity in species containing AIL genes suggests that exploiting APA genes variability in the Phaseolus genus may represent a valuable tool to find new members that may have acquired insecticidal activities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3820-5 [10759552.001]
  • [Cites] Plant Physiol. 1990 Jun;93(2):805-10 [16667540.001]
  • [Cites] Eur J Biochem. 2002 Jan;269(2):397-412 [11856298.001]
  • [Cites] Phytochemistry. 1996 Sep;43(1):57-62 [8987505.001]
  • [Cites] Theor Appl Genet. 2004 Apr;108(6):1098-102 [15067396.001]
  • [Cites] FASEB J. 1990 Nov;4(14 ):3198-208 [2227211.001]
  • [Cites] Theor Appl Genet. 2003 Sep;107(5):814-22 [12819911.001]
  • [Cites] Plant Mol Biol. 1994 Nov;26(4):1103-13 [7811969.001]
  • [Cites] Gut. 1995 Sep;37(3):353-60 [7590430.001]
  • [Cites] Plant Cell. 1991 Jan;3(1):1-9 [1824332.001]
  • [Cites] Eur J Biochem. 1984 May 15;141(1):97-104 [6723668.001]
  • [Cites] Curr Opin Plant Biol. 2005 Apr;8(2):129-34 [15752991.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Oct;86(20):7885-9 [2682631.001]
  • [Cites] Plant Physiol. 1972 Feb;49(2):187-9 [16657921.001]
  • [Cites] Planta. 1978 Jan;142(3):291-8 [24408192.001]
  • [Cites] Phytochemistry. 2001 Sep;58(1):59-66 [11524114.001]
  • [Cites] Biochim Biophys Acta. 1996 Jan 4;1292(1):15-22 [8547338.001]
  • [Cites] Plant Physiol. 1993 Apr;101(4):1341-8 [8310064.001]
  • [Cites] Food Chem Toxicol. 2003 Jan;41(1):21-7 [12453724.001]
  • [Cites] Mol Plant Microbe Interact. 2001 Aug;14(8):955-61 [11497467.001]
  • [Cites] Biochim Biophys Acta. 1998 Mar 3;1383(1):9-36 [9546043.001]
  • [Cites] Bioinformatics. 2001 Aug;17(8):754-5 [11524383.001]
  • [Cites] Biochim Biophys Acta. 2004 Feb 12;1696(2):181-90 [14871659.001]
  • [Cites] J Insect Physiol. 2000 Apr;46(4):393-402 [12770203.001]
  • [Cites] J Protein Chem. 2002 Jan;21(1):9-17 [11902670.001]
  • [Cites] Biochim Biophys Acta. 1998 Feb 17;1382(2):311-23 [9540803.001]
  • [Cites] Phytochemistry. 2006 Sep;67(18):2009-16 [16901522.001]
  • [Cites] Anal Biochem. 1981 Apr;112(2):195-203 [6266278.001]
  • [Cites] Plant Mol Biol. 2001 Mar;45(5):587-97 [11414617.001]
  • [Cites] Comput Appl Biosci. 1996 Dec;12(6):543-8 [9021275.001]
  • (PMID = 17701394.001).
  • [ISSN] 0040-5752
  • [Journal-full-title] TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik
  • [ISO-abbreviation] Theor. Appl. Genet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Phytohemagglutinins; 0 / Plant Lectins; 0 / alpha-amylase inhibitor, Phaseolus vulgaris; EC 3.2.1.1 / alpha-Amylases
  •  go-up   go-down


62. Samocha KE, Lim JE, Cheng R, Sokoloff G, Palmer AA: Fine mapping of QTL for prepulse inhibition in LG/J and SM/J mice using F(2) and advanced intercross lines. Genes Brain Behav; 2010 Oct;9(7):759-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine mapping of QTL for prepulse inhibition in LG/J and SM/J mice using F(2) and advanced intercross lines.
  • Humans with neurological and psychiatric disorders, including schizophrenia, obsessive-compulsive disorder and Huntington's disease, exhibit a reduction in PPI.
  • In order to elucidate the genes involved in sensorimotor gating, we phenotyped 472 mice from an F(2) cross between LG/J × SM/J for PPI and genotyped these mice genome-wide using 162 single nucleotide polymorphism (SNP) markers.
  • We also phenotyped 135 mice from an F(34) advanced intercross line (AIL) between LG/J × SM/J for PPI and genotyped them at more than 3000 SNP markers.
  • Inclusions of data from the AIL mice reduced the size of several of these QTLs to less than 5 cM.
  • These results will be useful for identifying genes that influence sensorimotor gaiting and show the power of AIL for fine mapping of QTLs.

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Genes, Brain and Behavior © 2010 Blackwell Publishing Ltd and International Behavioural and Neural Genetics Society.
  • [Cites] Biol Psychiatry. 1993 Feb 15;33(4):298-301 [8471686.001]
  • [Cites] Arch Gen Psychiatry. 1992 Mar;49(3):206-15 [1567275.001]
  • [Cites] Genetics. 1995 Nov;141(3):1199-207 [8582624.001]
  • [Cites] Br J Med Psychol. 1961;34:103-16 [13773940.001]
  • [Cites] Biol Psychiatry. 2005 May 15;57(10):1153-8 [15866555.001]
  • [Cites] Genet Res. 2005 Jun;85(3):211-22 [16174340.001]
  • [Cites] Genetics. 2005 Dec;171(4):1895-904 [15998716.001]
  • [Cites] Heredity (Edinb). 1992 Oct;69(4):315-24 [16718932.001]
  • [Cites] Arch Gen Psychiatry. 2007 Nov;64(11):1242-50 [17984393.001]
  • [Cites] PLoS Biol. 2007 Nov;5(11):e297 [18001149.001]
  • [Cites] Biol Psychiatry. 2007 Dec 15;62(12):1418-22 [17481589.001]
  • [Cites] Pharmacol Biochem Behav. 2008 Oct;90(4):525-33 [18513787.001]
  • [Cites] Biol Psychiatry. 2009 Mar 1;65(5):401-8 [19013555.001]
  • [Cites] Schizophr Res. 2009 Jun;111(1-3):182-91 [19351577.001]
  • [Cites] Neurosci Res. 2009 Nov;65(3):259-62 [19660506.001]
  • [Cites] Genes Brain Behav. 2009 Nov;8(8):806-16 [19694817.001]
  • [Cites] Genetics. 2010 Jul;185(3):1033-44 [20439773.001]
  • [Cites] Behav Neurosci. 2000 Apr;114(2):374-88 [10832798.001]
  • [Cites] Am J Psychiatry. 2000 Oct;157(10):1660-8 [11007721.001]
  • [Cites] Psychopharmacology (Berl). 2001 Jul;156(2-3):117-54 [11549216.001]
  • [Cites] Biol Psychiatry. 2001 Sep 15;50(6):418-24 [11566158.001]
  • [Cites] Genome Res. 2002 Apr;12(4):618-26 [11932246.001]
  • [Cites] Neuropsychopharmacology. 2002 Nov;27(5):765-81 [12431851.001]
  • [Cites] Psychopharmacology (Berl). 2003 Jan;165(3):270-9 [12426667.001]
  • [Cites] Bioinformatics. 2003 May 1;19(7):889-90 [12724300.001]
  • [Cites] Behav Neurosci. 2003 Aug;117(4):716-27 [12931957.001]
  • [Cites] J Neurosci Res. 2003 Nov 15;74(4):562-9 [14598300.001]
  • [Cites] Neurosci Lett. 2003 Dec 15;353(1):45-8 [14642434.001]
  • [Cites] Psychopharmacology (Berl). 2004 Aug;174(4):452-62 [15300359.001]
  • [Cites] Genome Res. 2004 Sep;14(9):1806-11 [15342563.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):192-200 [7876851.001]
  • (PMID = 20597988.001).
  • [ISSN] 1601-183X
  • [Journal-full-title] Genes, brain, and behavior
  • [ISO-abbreviation] Genes Brain Behav.
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / T32 MH020065; United States / NIMH NIH HHS / MH / R01 MH079103; United States / NIDA NIH HHS / DA / R01 DA021336; United States / NIDA NIH HHS / DA / R21DA024845; United States / NIDA NIH HHS / DA / R01DA021336; United States / NIMH NIH HHS / MH / T32MH020065; United States / NIDA NIH HHS / DA / R21 DA024845
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Other-IDs] NLM/ NIHMS490035; NLM/ PMC3749925
  •  go-up   go-down


63. Kasteng F, Erlanson M, Hagberg H, Kimby E, Relander T, Lundkvist J: Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. Acta Oncol; 2008;47(6):1029-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effect measures were quality-adjusted life-years (QALY) and life-years gained (LYG).
  • RESULTS: The evaluation assessed rituximab maintenance therapy to be associated with an incremental cost per QALY gained of euro 12,600 and an incremental cost per LYG of euro 11,200.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cost-Benefit Analysis. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Quality-Adjusted Life Years. Remission Induction. Rituximab. Sweden. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607857.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


64. Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Krämer A, Siebert U: Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany. GMS Health Technol Assess; 2010;6:Doc05
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESEARCH QUESTIONS: What is the long-term clinical effectiveness (reduction in lifetime risk of cervical cancer and death due to cervical cancer, life years gained) of HPV testing and what is the cost-effectiveness in Euro per life year gained (LYG) of including HPV testing in primary cervical cancer screening in the German health care context?
  • RESULTS: In the base case analysis screening resulted in a 53% to 97% risk reduction for cervical cancer with a discounted ICER between 2,600 Euro/LYG (cytology alone every five years) and 155,500 Euro/LYG (Annual cytology age 20 to 29 years, and annual HPV age 30 years and older).
  • An optimal strategy may be biennial HPV testing age 30 years and older with biennial cytology at age 25 to 29 years (ICER of 23,400 Euro/LYG).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21289878.001).
  • [ISSN] 1861-8863
  • [Journal-full-title] GMS health technology assessment
  • [ISO-abbreviation] GMS Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3010885
  • [Keywords] NOTNLM ; DNA / HPV / HPV-DNA diagnosis / Health Technology Assessment / Markov model / cancer / carcinoma / cervical carcinoma / cervix / cervix of uterus / cost-effectiveness / cytology / decision-analytical modelling / diagnosis / early finding / effectiveness / health economic evaluation / human papillomavirus / long-term effectiveness / meta-analysis / primary screening / screening / systematic review / test
  •  go-up   go-down


65. Kawai N, Miyake K, Nishiyama Y, Yamamoto Y, Sasakawa Y, Haba R, Kushida Y, Tamiya T, Nagao S: FDG-PET findings of the brain in lymphomatoid granulomatosis. Ann Nucl Med; 2006 Dec;20(10):683-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET findings of the brain in lymphomatoid granulomatosis.
  • Although 18F-fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) did not display a significant increase in FDG accumulation in the bilateral frontal and parietal white matter, kinetic analysis of this scan showed increased hexokinase activity in the lesions compared to the unaffected occipital white matter.
  • Diagnosis was made by open biopsy of the right frontal lobe and pathologic specimen was positive for lymphomatoid granulomatosis (LYG).
  • The patient received high-dose methotrexate with CHOP (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisolone) chemotherapy and follow-up MRI showed improvement of the lesions.
  • [18F]FDG-PET study with kinetic analysis may be useful to diagnose LYG in the central nervous system.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain / radionuclide imaging. Brain Neoplasms / drug therapy. Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Lymphomatoid Granulomatosis / drug therapy. Lymphomatoid Granulomatosis / radionuclide imaging

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17385307.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


66. Bonardi S, Paris A, Bassi L, Salmi F, Bacci C, Riboldi E, Boni E, D'Incau M, Tagliabue S, Brindani F: Detection, semiquantitative enumeration, and antimicrobial susceptibility of Yersinia enterocolitica in pork and chicken meats in Italy. J Food Prot; 2010 Oct;73(10):1785-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All isolates were tested for yadA, ail, inv, ystA, and ystB virulence sequences.
  • The yadA gene was detected in two strains (3.7%) isolated from chicken samples: one Y. enterocolitica 2/O:9 yadA+ ail+ ystA+, and one Y. enterocolitica 1A/O:7,8-8-8,19 yadA+ inv+ ystB+.
  • Two (3.7%) 2/O:9 strains, isolated from pork products, were ail+ ystA+.

  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • MedlinePlus Health Information. consumer health - Foodborne Illness.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21067665.001).
  • [ISSN] 0362-028X
  • [Journal-full-title] Journal of food protection
  • [ISO-abbreviation] J. Food Prot.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


67. Ferrara F, Ravasio R: Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma. Clin Drug Investig; 2008;28(1):55-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The model provided an estimate of mean survival (life-years gained [LYG]) and mean costs (direct medical costs) over a period of 3 years.
  • RESULTS: The LYG with the R-CHOP regimen was higher (2.697 LYG per patient) than with the CHOP regimen (2.517 LYG per patient).
  • Sensitivity analyses showed that the incremental cost-effectiveness ratios per LYG for complete response at 5 months (16,816.00 euro) and for relapse-free survival at 3 years (11,967.12 euro) were below the internationally accepted threshold (50,000 euro).
  • Furthermore, for survival at 3 years, R-CHOP was confirmed as the dominant therapy (lower expected mean costs, higher number of LYG).
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antibodies, Monoclonal, Murine-Derived. Cost-Benefit Analysis. Cyclophosphamide / administration & dosage. Cyclophosphamide / economics. Cyclophosphamide / therapeutic use. Decision Trees. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Doxorubicin / economics. Doxorubicin / therapeutic use. Humans. Injections, Intravenous. Prednisone / administration & dosage. Prednisone / economics. Prednisone / therapeutic use. Prognosis. Reproducibility of Results. Rituximab. Time Factors. Treatment Outcome. Vincristine / administration & dosage. Vincristine / economics. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Drug Investig. 2008;28(7):461-2; author reply 462-3 [18544006.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Value Health. 2005 Jul-Aug;8(4):462-70 [16091023.001]
  • [Cites] Health Technol Assess. 2004 Sep;8(37):iii, ix-xi, 1-82 [15361313.001]
  • [Cites] Postgrad Med J. 1999 Jan;75(879):2-6 [10396578.001]
  • [Cites] Risk Anal. 1995 Jun;15(3):369-90 [7604170.001]
  • [Cites] Leuk Lymphoma. 2006 Dec;47(12):2558-66 [17169800.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Pharmacoeconomics. 2004;22 Suppl 4:5-10 [15876007.001]
  • [Cites] Ann Hematol. 2007 Feb;86(2):107-15 [17103169.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:241-62 [12446426.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):588-95 [7884420.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1605-9 [15370212.001]
  • [Cites] Eur J Haematol. 2005 Mar;74(3):194-202 [15693788.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Haematologica. 2002 Aug;87(8):816-21 [12161357.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1644-51 [15756658.001]
  • [Cites] Cancer Invest. 2006 Oct;24(6):593-600 [16982464.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • (PMID = 18081361.001).
  • [ISSN] 1173-2563
  • [Journal-full-title] Clinical drug investigation
  • [ISO-abbreviation] Clin Drug Investig
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol, modified
  •  go-up   go-down


68. Thavorn K, Chaiyakunapruk N: A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand. Tob Control; 2008 Jun;17(3):177-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MAIN OUTCOME MEASURE: Cost per life year gained (LYG) attributable to the smoking cessation programme.
  • This finding provides important information for health policy decision-makers when determining the magnitude of resources to be allocated to smoking cessation service in community pharmacy.
  • [MeSH-minor] Adult. Cost-Benefit Analysis / statistics & numerical data. Female. Heart Diseases / economics. Humans. Lung Neoplasms / economics. Male. Markov Chains. Middle Aged. Program Evaluation. Pulmonary Disease, Chronic Obstructive / economics. Thailand

  • MedlinePlus Health Information. consumer health - Quitting Smoking.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18285385.001).
  • [ISSN] 1468-3318
  • [Journal-full-title] Tobacco control
  • [ISO-abbreviation] Tob Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


69. Macedo A, Monteiro I, Andrade S, Cirrincione A, Ray J: [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal]. Acta Med Port; 2010 May-Jun;23(3):475-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Custo-efectividade de trastuzumab no tratamento de doentes com cancro da mama em estádios iniciais em Portugal.
  • INTRODUCTION: Despite the important advances observed in the last 25 years in the comprehension of the clinical and biological nature of breast cancer and its treatment, this disease remains a significant cause of cancer morbidity and mortality worldwide.
  • The incremental cost-effectiveness ratios per life year gained (LYG) and per quality adjusted life year (QALY) gained were estimated.


70. Paudel KP, Kumar S, Meur SK, Kumaresan A: Ascorbic acid, catalase and chlorpromazine reduce cryopreservation-induced damages to crossbred bull spermatozoa. Reprod Domest Anim; 2010 Apr;45(2):256-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The proportion of acrosome intact live (AIL), acrosome intact dead, acrosome reacted live and acrosome reacted dead sperm was assessed in fresh, equilibrated and frozen-thawed semen.
  • In cryopreserved semen, the values of AIL spermatozoa, HOSST response, hyaluronidase and acrosin activity were reduced by 53%, 47%, 34% and 54%, respectively from their initial values in fresh semen.
  • The percentage of AIL sperm was significantly (p < 0.05) higher in ascorbic acid, catalase and ascorbic acid + chlorpromazine incorporated groups compared with the control.

  • MedlinePlus Health Information. consumer health - Vitamin C.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. Chlorpromazine .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19032433.001).
  • [ISSN] 1439-0531
  • [Journal-full-title] Reproduction in domestic animals = Zuchthygiene
  • [ISO-abbreviation] Reprod. Domest. Anim.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cryoprotective Agents; EC 1.11.1.6 / Catalase; PQ6CK8PD0R / Ascorbic Acid; U42B7VYA4P / Chlorpromazine
  •  go-up   go-down


71. Pullarkat VA, Medeiros LJ, Brynes RK: Body cavity-based presentation of natural killer cell lymphoma. Leuk Lymphoma; 2005 Feb;46(2):293-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extranodal NK/T-cell lymphoma of nasal type is the current designation for these neoplasms in the recently proposed World Health Organization classification of lymphoid neoplasms.
  • These tumors previously have been referred to many other names, including lethal midline granuloma, midline malignant reticulosis, polymorphic reticulosis, angiocentric immunoproliferative lesion, and angiocentric lymphoma.
  • The malignant cytologic features and the presence of azurophilic granules within the cell cytoplasm observed in Wright-Giemsa-stained cytocentrifuge preparations led to immunophenotypic and molecular genetic studies that were essential in establishing the correct diagnosis.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell / pathology. Nose Neoplasms / diagnosis. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Herpesvirus 4, Human / isolation & purification. Humans. Pleural Cavity / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621817.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


72. Warolin C: [The opiate pharmacopeia in France from its origins to the 19th century]. Rev Hist Pharm (Paris); 2010 Apr;58(365):81-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sydenham's laudanum (1683) was adopted by ail the pharmacopeias.
  • Seguin, but above ail the German pharmacist Sertürner (in 1805 and 1817) isolated morphine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20533811.001).
  • [ISSN] 0035-2349
  • [Journal-full-title] Revue d'histoire de la pharmacie
  • [ISO-abbreviation] Rev Hist Pharm (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Historical Article; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 8008-60-4 / Opium
  •  go-up   go-down


73. Joseph R, Chacko B, Manipadam MT, Sureka J, Cherian VK, John GT: Pulmonary lymphomatoid granulomatosis in a renal allograft recipient. Transpl Infect Dis; 2008 Feb;10(1):52-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary lymphomatoid granulomatosis in a renal allograft recipient.
  • Lymphomatoid granulomatosis (LYG) is a rare multisystemic angiocentric lymphoproliferative disease, which can masquerade as necrotic tissue.
  • There is a paucity of reports of LYG in renal transplant recipients.
  • Herein, we describe LYG in a 56-year-old renal allograft recipient 11 years after transplantation, on azathioprine and prednisolone maintenance immunosuppression, presenting to us with fever, weight loss, and nodular and patchy opacities in both lung fields.
  • We have reviewed the radiological and pathological findings, and discussed clinical features, differential diagnosis, and treatment of LYG.
  • [MeSH-major] Kidney Transplantation / adverse effects. Lung Neoplasms. Lymphomatoid Granulomatosis. Transplantation, Homologous / adverse effects


74. Kolodziejek AM, Sinclair DJ, Seo KS, Schnider DR, Deobald CF, Rohde HN, Viall AK, Minnich SS, Hovde CJ, Minnich SA, Bohach GA: Phenotypic characterization of OmpX, an Ail homologue of Yersinia pestis KIM. Microbiology; 2007 Sep;153(Pt 9):2941-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic characterization of OmpX, an Ail homologue of Yersinia pestis KIM.
  • For Yersinia enterocolitica and Yersinia pseudotuberculosis, Ail, YadA and Inv, have been implicated in these processes.
  • Genomic analysis of two Y. pestis strains revealed four loci with sequence homology to Ail.
  • The mature protein has a predicted molecular mass of 17.47 kDa, shares approximately 70 % sequence identity with Y. enterocolitica Ail, and has an identical homologue, designated Ail, in the Y. pestis CO92 database.
  • The parental strain (and a merodiploid control strain) expressed OmpX at 28 and 37 degrees C, and the protein was detectable throughout all phases of growth.
  • These results suggest that Y. pestis OmpX shares functional homology with Y. enterocolitica Ail in adherence, internalization into epithelial cells and serum resistance.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768237.001).
  • [ISSN] 1350-0872
  • [Journal-full-title] Microbiology (Reading, England)
  • [ISO-abbreviation] Microbiology (Reading, Engl.)
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016454; United States / NCRR NIH HHS / RR / P20 RR15587; United States / NIAID NIH HHS / AI / U54AI57141
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ail protein, Yersinia enterocolitica; 0 / Bacterial Outer Membrane Proteins; 0 / Proteome; EC 3.- / Hydrolases
  •  go-up   go-down


75. Kodama K, Oda K, Okami J, Maeda J, Wang L, Higashiyama M, Nakayama T: [The value of long-term postoperative follow-up after curative resection of lung cancer and common problems associated with it]. Nihon Geka Gakkai Zasshi; 2007 May;108(3):107-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For the calculation of the costs per life-year gained (LYG) of our follow-up program, an estimated survival benefit of 226 days was used.
  • Consequently, the costs per LYG were calculated at almost 4,500,000 yen.
  • In conclusion, the costs per LYG seem to be acceptable in the light of Japanese average annual earnings.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17533945.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


76. de la Cámara R, Jarque I, Sanz MA, Grau S, Casado MA, Sabater FJ, Carreras E: Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT. Bone Marrow Transplant; 2010 May;45(5):925-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A decision-analytic model was developed to assess the average per patient treatment costs, IFIs avoided, life-years gained (LYG) and incremental cost per LYG for each prophylactic treatment used (in euros at 2007 prices).
  • Posaconazole was associated with fewer IFIs (5.3 vs 9%), increased LYG (8.01 vs 7.78) and higher IFI-related costs ([euro]11 585 vs [euro]6 959) per patient compared with fluconazole.
  • The incremental cost-effectiveness of posaconazole vs fluconazole was estimated at [euro]20 246 per LYG.
  • There was a 70% probability that posaconazole is cost-effective at a [euro]30 000 per LYG threshold.
  • [MeSH-major] Fluconazole / economics. Fluconazole / therapeutic use. Graft vs Host Disease / therapy. Mycoses / prevention & control. Triazoles / economics. Triazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Bone Marrow Transplant. 2010 May;45(5):966
  • (PMID = 19802030.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Triazoles; 6TK1G07BHZ / posaconazole; 8VZV102JFY / Fluconazole
  •  go-up   go-down


77. Percik R, Serr J, Segal G, Stienlauf S, Trau H, Shalmon B, Shimoni A, Sidi Y: Lymphomatoid granulomatosis: a diagnostic challenge. Isr Med Assoc J; 2005 Mar;7(3):198-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid granulomatosis: a diagnostic challenge.
  • [MeSH-major] Lymphomatoid Granulomatosis / diagnosis

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792271.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


78. Seifried C, Weidauer S, Hinsch N, Bug R, Steinmetz H: [Cerebral lymphomatoid granulomatosis. A case report]. Nervenarzt; 2007 Feb;78(2):193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cerebral lymphomatoid granulomatosis. A case report].
  • [Transliterated title] Zerebrale lymphomatoide Granulomatose. Ein Fallbericht.
  • MR imaging revealed multiple lesions, particularly in the subcortical white matter, with spot like central contrast enhancement.
  • The diagnosis of lymphomatoid granulomatosis was finally made through open lung biopsy.
  • Despite treatment with rituximab and, in the later course of the disease, additionally with cyclophosphamide, the patient died 3 months after the diagnosis was made.
  • [MeSH-major] Brain Neoplasms / complications. Confusion / etiology. Fever of Unknown Origin / etiology. Lymphomatoid Granulomatosis / complications. Magnetic Resonance Imaging. Radiography, Thoracic. Tomography, X-Ray Computed


79. Soini EJ, Davies G, Martikainen JA, Hu HX, Tunceli K, Niskanen L: Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Curr Med Res Opin; 2010 Jan;26(1):25-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland.
  • OBJECTIVE: To evaluate the cost-effectiveness of generic atorvastatin 20 mg (A20), branded rosuvastatin 10 mg (R10), generic simvastatin 40 mg (S40) and the combination of generic S40 + branded ezetimibe 10 mg (S40 + EZ10) for the secondary prevention of coronary heart disease (CHD) in Finnish patients not meeting the target goal of low-density lipoprotein cholesterol (LDL-C) with S40.
  • MAIN OUTCOME MEASURES: Incremental cost per quality-adjusted life year (QALY) gained and incremental cost per life year gained (LYG).
  • [MeSH-major] Coronary Disease / prevention & control. Cost of Illness

  • Genetic Alliance. consumer health - Heart Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895364.001).
  • [ISSN] 1473-4877
  • [Journal-full-title] Current medical research and opinion
  • [ISO-abbreviation] Curr Med Res Opin
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholesterol, LDL
  •  go-up   go-down


80. Nishihara H, Tateishi U, Itoh T, Nagashima K, Tanaka S: Immunohistochemical and gene rearrangement studies of central nervous system lymphomatoid granulomatosis. Neuropathology; 2007 Oct;27(5):413-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical and gene rearrangement studies of central nervous system lymphomatoid granulomatosis.
  • Lymphomatoid granulomatosis (LYG) is a rare multisystem disorder with characteristic angiocentric lymphoproliferative features, most frequently involving the lung, skin, and rarely the CNS.
  • LYG has been classified into three subtypes based on the relative proportions of atypical and inflammatory infiltrating cells.
  • Most systemic LYGs have been shown to be EBV-associated, T-cell rich, B-cell proliferative disorders.
  • Here, we present four cases of LYG arising from the CNS and have analyzed them by immunohistochemistry to assess the phenotype of the infiltrate, and by PCR-SSCP (single-strand conformation polymorphism) analysis for immunoglobulin heavy chain (IgH) and T-cell receptor (TcR) gamma gene rearrangements.
  • Three cases revealed perivascular infiltration of T-cell dominant lymphoid cells, two cases showed monoclonal TcRgamma gene rearrangement, while the remaining case had a B-cell immunophenotype and monoclonal IgH gene rearrangement with EBV genome expression.
  • This is the first report of a gene rearrangement study on CNS-LYG.
  • We confirm that some cases of CNS-LYG are derived from T-cell monoclonal lymphoproliferative disease, although this disease should be classified as a borderline malignancy and should be separated from overt malignant lymphoma of CNS.
  • [MeSH-major] Central Nervous System Diseases / pathology. Gene Rearrangement. Genes, T-Cell Receptor gamma. Immunoglobulin Heavy Chains / genetics. Lymphomatoid Granulomatosis / pathology

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018473.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


81. Martín-Jiménez M, Rodríguez-Lescure A, Ruiz-Borrego M, Seguí-Palmer MA, Brosa-Riestra M: Cost-effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer. Clin Transl Oncol; 2009 Jan;11(1):41-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Results are shown as cost per life year gained (C/LYG) and cost per quality-adjusted life year (C/QALY).
  • The results of the cost-effectiveness analysis showed that TAC achieves a C/LYG and a C/QALY of only euro2345 and euro2631, respectively.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2713-25 [12039934.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1205-12 [16766587.001]
  • [Cites] N Engl J Med. 2005 Jun 2;352(22):2302-13 [15930421.001]
  • [Cites] Oncologist. 2003;8(3):232-40 [12773745.001]
  • [Cites] Pharmacoeconomics. 1997 May;11(5):492-7 [10168037.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(2):215-22 [12509954.001]
  • [Cites] Value Health. 2004 Jan-Feb;7(1):70-8 [14720132.001]
  • [Cites] Gac Sanit. 2002 Jul-Aug;16(4):334-43 [12113733.001]
  • [Cites] Med Decis Making. 1997 Apr-Jun;17(2):152-9 [9107610.001]
  • [Cites] Am J Health Syst Pharm. 1997 Dec 15;54(24 Suppl 2):S11-5 [9435927.001]
  • [Cites] Pharmacoeconomics. 1996 Nov;10(5):504-21 [10169397.001]
  • [Cites] Med Decis Making. 1983;3(4):419-458 [6668990.001]
  • [Cites] N Engl J Med. 2003 Nov 6;349(19):1793-802 [14551341.001]
  • [Cites] Pharmacoeconomics. 1998 Apr;13(4):397-409 [10178664.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2738-46 [8874335.001]
  • (PMID = 19155203.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


82. Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LT, Postma MJ, PREVEND IT Study Group: Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clin Ther; 2006 Mar;28(3):432-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
  • OBJECTIVE: This study estimated the cost-effectiveness,from the Dutch health care perspective, of screening for albuminuria in the general Dutch population to prevent cardiovascular events (CVEs) with subsequent angiotensin-converting enzyme inhibitor treatment, using data from the Prevention of REnal and Vascular ENdstage Disease Intervention Trial (PREVEND IT).
  • METHODS: PREVEND IT was a single-center, double-blind, randomized, placebo-controlled trial with a 2 x 2 factorial design within the larger observational Prevention of REnal and Vascular ENdstage Disease (PREVEND) study.
  • Cost-effectiveness estimates for the Dutch population were expressed in euros (2002; 1 euro = US 1.01 dollars) as net costs per life-year gained (LYG) in the baseline and sensitivity (stochastic) analyses.
  • The cost-effectiveness of screening for albumnuria was determined to be euro 16,700/LYG for the study population.
  • Stochastic analysis indicated that the probability of the cost-effectiveness being below the suggested Dutch threshold of euro 20,000/LYG was 59% in the baseline analysis.
  • The probability of cost-effectiveness below euro 20,000/LYG would increase to 91% if only subjects with UAE >50 mg/d were treated with fosinopril.


83. Peirce JL, Broman KW, Lu L, Chesler EJ, Zhou G, Airey DC, Birmingham AE, Williams RW: Genome Reshuffling for Advanced Intercross Permutation (GRAIP): simulation and permutation for advanced intercross population analysis. PLoS One; 2008 Apr 23;3(4):e1977
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Advanced intercross lines (AIL) are segregating populations created using a multi-generation breeding protocol for fine mapping complex trait loci (QTL) in mice and other organisms.
  • Applying QTL mapping methods for intercross and backcross populations, often followed by naïve permutation of individuals and phenotypes, does not account for the effect of AIL family structure in which final generations have been expanded and leads to inappropriately low significance thresholds.
  • The critical problem with naïve mapping approaches in AIL populations is that the individual is not an exchangeable unit.
  • METHODOLOGY/PRINCIPAL FINDINGS: The effect of family structure has immediate implications for the optimal AIL creation (many crosses, few animals per cross, and population expansion before the final generation) and we discuss these and the utility of AIL populations for QTL fine mapping.
  • We also describe Genome Reshuffling for Advanced Intercross Permutation, (GRAIP) a method for analyzing AIL data that accounts for family structure.
  • GRAIP permutes a more interchangeable unit in the final generation crosses - the parental genome - and simulating regeneration of a permuted AIL population based on exchanged parental identities.
  • GRAIP determines appropriate genome-wide significance thresholds and locus-specific P-values for AILs and other populations with similar family structures.
  • We contrast GRAIP with naïve permutation using a large densely genotyped mouse AIL population (1333 individuals from 32 crosses).
  • GRAIP also detects an established hippocampus weight locus and a new locus, Hipp9a.
  • CONCLUSIONS AND SIGNIFICANCE: GRAIP determines appropriate genome-wide significance thresholds and locus-specific P-values for AILs and other populations with similar family structures.
  • The effect of family structure has immediate implications for the optimal AIL creation and we discuss these and the utility of AIL populations.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mamm Genome. 2000 Aug;11(8):645-8 [10920233.001]
  • [Cites] PLoS One. 2007;2(10):e1036 [17940600.001]
  • [Cites] J Neurosci. 2001 May 15;21(10):3503-14 [11331379.001]
  • [Cites] Genomics. 2001 May 15;74(1):89-104 [11374905.001]
  • [Cites] Genetics. 2001 Sep;159(1):371-87 [11560912.001]
  • [Cites] Hum Hered. 2001;52(3):121-31 [11588394.001]
  • [Cites] Genome Biol. 2001;2(11):RESEARCH0046 [11737945.001]
  • [Cites] Am J Hum Genet. 2002 Apr;70(4):920-34 [11880950.001]
  • [Cites] Genetics. 2002 Mar;160(3):1123-31 [11901128.001]
  • [Cites] Nat Genet. 2002 Jul;31(3):235-6 [12089518.001]
  • [Cites] Neuropsychopharmacology. 2003 Apr;28(4):818; author reply 819 [12655329.001]
  • [Cites] Bioinformatics. 2003 May 1;19(7):889-90 [12724300.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3317-24 [12810665.001]
  • [Cites] Genome Res. 2003 Jul;13(7):1654-64 [12805272.001]
  • [Cites] Genes Brain Behav. 2003 Aug;2(4):238-52 [12953790.001]
  • [Cites] Nat Rev Genet. 2003 Nov;4(11):911-6 [14634638.001]
  • [Cites] Neuroinformatics. 2003;1(4):343-57 [15043220.001]
  • [Cites] BMC Genet. 2004 Apr 29;5:7 [15117419.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1366-73 [15240732.001]
  • [Cites] Mamm Genome. 2004 Aug;15(8):637-47 [15457343.001]
  • [Cites] Nat Genet. 2004 Nov;36(11):1133-7 [15514660.001]
  • [Cites] J Dairy Sci. 1990 Sep;73(9):2525-37 [2258496.001]
  • [Cites] Genetics. 1994 Nov;138(3):963-71 [7851788.001]
  • [Cites] Genetics. 1995 Nov;141(3):1199-207 [8582624.001]
  • [Cites] Am J Hum Genet. 1996 Jun;58(6):1323-37 [8651310.001]
  • [Cites] Mamm Genome. 1999 Apr;10(4):335-48 [10087289.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Apr;40(5):817-25 [10102277.001]
  • [Cites] Genetics. 2005 Feb;169(2):1133-46 [15545647.001]
  • [Cites] Nat Genet. 2005 Mar;37(3):233-42 [15711545.001]
  • [Cites] Genetics. 2005 May;170(1):283-9 [15716504.001]
  • [Cites] Genetics. 2005 Jul;170(3):1299-311 [15879512.001]
  • [Cites] Mamm Genome. 2005 May;16(5):344-55 [16104382.001]
  • [Cites] Exp Lung Res. 2000 Dec;26(8):641-9 [11195461.001]
  • (PMID = 18431467.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / U01AA01442501; United States / NIMH NIH HHS / MH / P20 MH062009; United States / NHLBI NIH HHS / HV / HV48141; United States / NIAAA NIH HHS / AA / U01 AA013499; United States / NIAAA NIH HHS / AA / U01AA13499; United States / NIAAA NIH HHS / AA / U24AA135B; United States / NIMH NIH HHS / MH / P20-MH62009; United States / NHLBI NIH HHS / HL / N01HV48141
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2295257
  •  go-up   go-down


84. Peterkin A: Medical humanities for what ails us. CMAJ; 2008 Feb 26;178(5):648
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical humanities for what ails us.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18299558.001).
  • [ISSN] 1488-2329
  • [Journal-full-title] CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • [ISO-abbreviation] CMAJ
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2244678
  •  go-up   go-down


85. Fidan D, Unal B, Critchley J, Capewell S: Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010. QJM; 2007 May;100(5):277-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
  • BACKGROUND: Coronary heart disease (CHD) in the UK affects approximately 3 million people, with >100,000 deaths annually.
  • METHODS: The IMPACT CHD model was used to calculate the number of life-years gained (LYG) from specific cardiological interventions from 2000 to 2010.
  • Cost-effectiveness ratios (costs per LYG) were generated for each specific intervention, stratified by age and sex.
  • Aspirin and beta-blockers for secondary prevention following myocardial infarction or revascularisation, for angina and heart failure were highly cost-effective (< 1000 pounds per LYG).
  • Other secondary prevention therapies, including cardiac rehabilitation, ACE inhibitors and statins, were reasonably cost-effective (1957 pounds, 3398 pounds and 4246 pounds per LYG, respectively), as were CABG surgery (3239 pounds-4601 pounds per LYG) and angioplasty (3845 pounds-5889 pounds per LYG).
  • Primary angioplasty for myocardial infarction was intermediate (6054 pounds-12,057 pounds per LYG, according to age), and statins in primary prevention were much less cost-effective (27,828 pounds per LYG, reaching 69,373 pounds per LYG in men aged 35-44).
  • [MeSH-major] Coronary Disease / economics. Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use

  • Genetic Alliance. consumer health - Heart Disease.
  • MedlinePlus Health Information. consumer health - Statins.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449875.001).
  • [ISSN] 1460-2725
  • [Journal-full-title] QJM : monthly journal of the Association of Physicians
  • [ISO-abbreviation] QJM
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Fibrinolytic Agents; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; R16CO5Y76E / Aspirin
  •  go-up   go-down


86. Halvani A, Owlia MB, Sami R: Lymphomatoid granulomatosis with splenomegaly and pancytopenia. Zhongguo Fei Ai Za Zhi; 2010 Jan;13(1):84-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid granulomatosis with splenomegaly and pancytopenia.
  • Lymphomatoid granulomatosis (LG) is an angiocentric lymphoproliferative disease.
  • It usually involves lung, skin, and central nervous system, but splenomegaly and pancytopenia are the rare manifestations of the disease.
  • We report a 15-year-old boy presented with fever, dry cough and dyspnea from two months ago, after admission patient had nodular lesions on the left leg and hepatosplenomegaly.
  • Skin biopsy was done, and histopathological examination and immunohistochemistry evaluation confirmed lymphomatoid granulomatosis.
  • [MeSH-major] Lymphomatoid Granulomatosis / diagnosis. Pancytopenia / diagnosis. Splenomegaly / diagnosis

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • Genetic Alliance. consumer health - Splenomegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20672711.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


87. Rodríguez J, Conde E, Gutiérrez A, Arranz R, Gandarillas M, Leon A, Ojanguren J, Sureda A, Carrera D, Bendandi M, Moraleda J, Ribera JM, Albo C, Morales A, García JC, Fernández P, Cañigral G, Bergua J, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea: Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol; 2007 Apr;78(4):290-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Angioimmunoblastic T-cell lymphoma (AIL) is a rare lymphoma with a poor prognosis and no standard treatment.
  • After a median follow-up of 25 months, eight patients died (seven of progressive disease and secondary neoplasia), while actuarial overall survival and progression-free survival at 3 yr was 60% and 55%.
  • Prognostic factors associated with a poor outcome included bone marrow involvement, transplantation in refractory disease state, attributing more than one factor of the age-adjusted-International Prognostic Index, Pretransplant peripheral T-cell lymphoma (PTCL) Score or Prognostic Index for PTCL.
  • CONCLUSIONS: More than half of the patients with AIL that display unfavourable prognostic factors at diagnosis or relapse would be expected to be alive and disease-free after 3 yr when treated with HDC/ASCT.
  • Patients who are transplanted in a refractory disease state do not benefit from this procedure.
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Registries. Severity of Illness Index. Spain. Survival Rate. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378891.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


88. Rogers DG, Aliano VA: Metastatic angioinvasive lymphoma (lymphomatoid granulomatosis) in a cat. J Vet Diagn Invest; 2009 May;21(3):390-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic angioinvasive lymphoma (lymphomatoid granulomatosis) in a cat.
  • A subcutaneous mass removed from the right rear leg of a 17-year-old, spayed, female Domestic Shorthair cat was characterized histopathologically by granulomatous inflammation, sheets of large atypical lymphoid cells, and necrosis.
  • The walls of the small and medium caliber blood vessels were invaded transmurally by atypical lymphoid cells.
  • A diagnosis of angioinvasive lymphoma (AIL), or lymphomatoid granulomatosis, was made based on histopathologic findings.
  • The cat was euthanized 2 months later because of recurrence of the mass and elevated serum alanine aminotransferase activity, and a necropsy was performed.
  • The histopathologic lesion of AIL was seen in the skin and subcutis of the right rear leg, and neoplastic cell infiltrates were seen in adjacent skeletal muscle, right superficial inguinal lymph node, liver, and spleen.
  • Although the cat had received a Rabies virus vaccine subcutaneously in the right rear leg 6 months earlier, the AIL lesion was not typical of vaccine-induced sarcomas.
  • The AIL in this cat was unusual because the extrapulmonary metastases involved the skin and subcutis.
  • [MeSH-major] Cat Diseases / diagnosis. Lymphomatoid Granulomatosis / veterinary. Neoplasms, Connective Tissue / veterinary

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407098.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Street A, Hill K, Sussex B, Warner M, Scully MF: Haemophilia and ageing. Haemophilia; 2006 Jul;12 Suppl 3:8-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Men with haemophilia have not only the challenges of living with HIV and/or HCV infection and premature arthritis as complications of their disorder, but they also confront the other ails of ageing.
  • These include genitourinary problems such as prostatic hypertrophy, prostatic cancer and renal stone disease, and arterial disease for which haemophilia is not protective.
  • Many older men with haemophilia may never have consulted primary care physicians because of the rarity and complexity of their disorder.
  • We need to be aware of the ageing issues in haemophilia and develop 'wellness' programs which are directed to the early identification of disease as well as preventative strategies to reduce the physical and psychological impacts of ageing.


90. He CN, Zhang J, Duan GC: [Clinicopathological characteristic of lymphomatoid granulomatosis]. Zhonghua Bing Li Xue Za Zhi; 2007 May;36(5):336-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological characteristic of lymphomatoid granulomatosis].
  • [MeSH-major] Lung Neoplasms. Lymphomatoid Granulomatosis
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Antiviral Agents / therapeutic use. Diagnosis, Differential. Granulomatosis with Polyangiitis / diagnosis. Humans. Prognosis. Sarcoidosis / diagnosis. Tuberculosis, Pulmonary / diagnosis

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706144.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antiviral Agents
  • [Number-of-references] 26
  •  go-up   go-down


91. Okuda T, Akai F, Kataoka K, Taneda M: A case of lymphomatoid granulomatosis followed for 14 months on the basis of clinical and histological findings. Brain Tumor Pathol; 2008;25(1):33-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of lymphomatoid granulomatosis followed for 14 months on the basis of clinical and histological findings.
  • Lymphomatoid granulomatosis (LYG) is a systemic granulomatous disease characterized by B-cell proliferation of uncertain malignant potential.
  • We recently encountered a case of LYG that was followed clinically and histologically for 14 months.
  • A 55-year-old man was hospitalized with multiple brain tumors for which the final diagnosis was not made until the second surgery, 14 months after the first intervention.
  • Following the diagnosis, he was treated with steroid pulse therapy.
  • At present, 3.5 years after the onset of LYG, the patient is in good condition with no signs of tumor recurrence.
  • Although LYG is usually graded on the basis of histological findings, this patient showed no histological changes or any increase in disease grade during the 14-month follow-up period.
  • [MeSH-major] Brain Neoplasms / pathology. Lymphomatoid Granulomatosis / pathology

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18415664.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


92. Footracer KG: Immigrant health care in the United States: what ails our system? JAAPA; 2009 Apr;22(4):33-6, 60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immigrant health care in the United States: what ails our system?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19452819.001).
  • [ISSN] 1547-1896
  • [Journal-full-title] JAAPA : official journal of the American Academy of Physician Assistants
  • [ISO-abbreviation] JAAPA
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


93. Furuta K, Nakagawa A, Morita K, Tajiri T, Nishiyama H, Nohgawa M, Ono K, Kobashi Y: [A case of lymphomatoid granulomatosis which initially demonstrated a diffuse ground glass appearance]. Nihon Kokyuki Gakkai Zasshi; 2010 Jan;48(1):49-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of lymphomatoid granulomatosis which initially demonstrated a diffuse ground glass appearance].
  • Lymphomatoid granulomatosis is defined as an Epstein-Barr virus-associated B-cell lymphoma which possibly progresses to malignant lymphoma.
  • The pulmonary lesions associated with this disease typically reveal multiple poorly defined nodules.
  • We finally diagnosed lymphomatoid granulomatosis (grade 2) based on the findings of a thoracoscopic lung biopsy.
  • Pathologically, an angiocentric proliferation of large atypical lymphoid cells were observed which were positive for EBER (EBV-encoded small RNA).
  • [MeSH-major] Lung / radiography. Lung Neoplasms / radiography. Lymphomatoid Granulomatosis / radiography

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20163022.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


94. Neyt M, De Laet C, Van Brabandt H, Franco O, Ramaekers D: Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium. Acta Cardiol; 2009 Feb;64(1):1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.
  • The aim of this study is to determine the cost-effectiveness of statins for the primary prevention of cardiovascular disease (CVD) in middle-aged Belgian populations.
  • Prescribing the cheapest statin on the Belgian market (< Euro 90 medication cost per year) resulted in an incremental cost of Euro 29,173 per life-year gained (LYG) in a male high-risk group aged 60 compared to low-dose aspirin.
  • The incremental cost in a male moderate-risk group aged 50 was Euro 87,022/LYG.
  • Low-dose aspirin was more cost-effective ranging from Euro 3,854/LYG to Euro 29,509/LYG compared to smoking cessation therapy.

  • MedlinePlus Health Information. consumer health - Statins.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317290.001).
  • [ISSN] 0001-5385
  • [Journal-full-title] Acta cardiologica
  • [ISO-abbreviation] Acta Cardiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Platelet Aggregation Inhibitors; R16CO5Y76E / Aspirin
  • [Number-of-references] 27
  •  go-up   go-down


95. Kun L: Interoperability: the cure for what ails us. IEEE Eng Med Biol Mag; 2007 Jan-Feb;26(1):87-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interoperability: the cure for what ails us.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17278776.001).
  • [ISSN] 0739-5175
  • [Journal-full-title] IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society
  • [ISO-abbreviation] IEEE Eng Med Biol Mag
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Vahid B, Salerno DA, Marik PE: Lymphomatoid granulomatosis: a rare cause of multiple pulmonary nodules. Respir Care; 2008 Sep;53(9):1227-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid granulomatosis: a rare cause of multiple pulmonary nodules.
  • [MeSH-major] Lung Neoplasms / pathology. Lymphomatoid Granulomatosis / pathology. Meningeal Neoplasms / secondary

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18718043.001).
  • [ISSN] 0020-1324
  • [Journal-full-title] Respiratory care
  • [ISO-abbreviation] Respir Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Lester B: Robots' allure: can it remedy what ails computer science? Science; 2007 Nov 16;318(5853):1086-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robots' allure: can it remedy what ails computer science?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006735.001).
  • [ISSN] 1095-9203
  • [Journal-full-title] Science (New York, N.Y.)
  • [ISO-abbreviation] Science
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down


98. Patsalides AD, Atac G, Hedge U, Janik J, Grant N, Jaffe ES, Dwyer A, Patronas NJ, Wilson WH: Lymphomatoid granulomatosis: abnormalities of the brain at MR imaging. Radiology; 2005 Oct;237(1):265-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid granulomatosis: abnormalities of the brain at MR imaging.
  • PURPOSE: To retrospectively evaluate the magnetic resonance (MR) imaging features of lymphomatoid granulomatosis in the brain.
  • Thirty-one patients with pathologically confirmed lymphomatoid granulomatosis were enrolled in a natural history and treatment study at the National Institutes of Health.
  • Twenty-five patients (median age, 50 years; range, 18-62 years; 18 men, seven women) were evaluated with MR imaging of the brain at study entry for the presence of brain lesions and enhancing characteristics.
  • Multiple focal intraparenchymal lesions, which exhibited T2 prolongation and commonly punctate or linear enhancement, were the most frequent abnormalities, and they were encountered in seven patients.
  • The second most common finding was involvement of leptomeninges and cranial nerves, which manifested as abnormal enhancement on MR images obtained after contrast agent administration.
  • This abnormality was seen in six patients.
  • Most lesions resolved after treatment, but seven resulted in lacunar infarctions.
  • CONCLUSION: Lymphomatoid granulomatosis has a high rate of central nervous system involvement and a variable spectrum of lesions at MR imaging.
  • Findings in this study suggest that MR imaging is more sensitive than CSF cytologic analysis or flow cytometry for detection of central nervous system involvement from lymphomatoid granulomatosis.
  • [MeSH-major] Brain / pathology. Lymphomatoid Granulomatosis / pathology. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2005
  • (PMID = 16100084.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Collins SR: Consumer-driven health care. Why it won't solve what ails the United States health system. J Leg Med; 2007 Jan-Mar;28(1):53-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consumer-driven health care. Why it won't solve what ails the United States health system.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17365413.001).
  • [ISSN] 0194-7648
  • [Journal-full-title] The Journal of legal medicine
  • [ISO-abbreviation] J Leg Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


100. Wu SM, Min Y, Ostrzega N, Clements PJ, Wong AL: Lymphomatoid granulomatosis: a rare mimicker of vasculitis. J Rheumatol; 2005 Nov;32(11):2242-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid granulomatosis: a rare mimicker of vasculitis.
  • Lymphomatoid granulomatosis (LG) is a rare Epstein-Barr virus-associated lymphoproliferative disorder, with a propensity for blood vessel destruction.
  • Since LG often mimics systemic vasculitis, it presents a diagnostic clinical challenge.
  • We describe a case of LG with no pulmonary involvement, which was thought to be systemic vasculitis on the basis of multiorgan involvement and biopsy findings.
  • [MeSH-major] Lymphoma / pathology. Lymphomatoid Granulomatosis / pathology. Vasculitis / pathology
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Humans. Male. Middle Aged. Tomography, X-Ray Computed






Advertisement